Design Therapeutics

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.

<ul>
<li>The MBA&#39;s index of mortgage application activity for the latest week is scheduled for release at 7:00 a.m. ET.</li>
<li>The current account report for the first quarter will be released at 8:30 a.m. ET. After a $188.5 billion deficit in the fourth quarter, a gap of $207.0 billion is expected for the first quarter.</li>
<li>Fed Governor Michelle Bowman is set to speak at 9:10 a.m. ET.</li>
<li>The flash Composite Purchasing Managers&#39; Index for June is scheduled for release at 9:45 a.m. ET. Analysts expect the index falling to 67.9 in June from 68.1 in the previous month.</li>
<li>Data on new home sales for May will be released at 10:00 a.m. ET. New home sales are expected to re-accelerate, to a 881,000 annual rate in May from April&#39;s 863,000.</li>
<li>The Energy Information Administration&rsquo;s weekly report on petroleum inventories is scheduled for released at 10:30 a.m. ET.</li>
<li>Raphael Bostic, Federal Reserve Bank of Atlanta president will speak at 11:10 a.m. ET.</li>
<li>The Treasury is set to auction 5-year notes at 1:00 p.m. ET.</li>
<li>Federal Reserve Bank of Boston President Eric Rosengren is set to speak at 4:30 p.m. ET.</li>
</ul>
<a href="https://www.benzinga.com/calendar/economics/">Check out the full economic calendar here </a>

News

Economics

Pre-Market Outlook

Markets

Economic Data Scheduled For Wednesday

Cathie Wood-led Ark Investment Management on Tuesday snapped up 214,718 shares, estimated to be worth about $47.76 million, in Coinbase Global Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>).&nbsp;
Shares of the cryptocurrency exchange, which have fallen about 7% over the past week, closed marginally lower at $222.47 on Tuesday.
Wood&rsquo;s firm deployed the Ark Innovation ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/arkk#NYSE">ARKK</a>) to buy the shares of the cryptocurrency exchange. The investment firm also holds the shares of the company via the Ark Next Generation Internet ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/arkw#NYSE">ARKW</a>) and the Ark Fintech Innovation ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/arkf#NYSE">ARKF</a>).
Ark&#39;s stake in COIN is currently valued at $1.05 billion with about 4.7 million shares. In comparison, Ark Invest holds about 4.86 million shares, worth about $3.04 billion on 4.9 million shares, in Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>), its largest holding.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21523897/cathie-wood-bullish-on-bitcoin-lifts-coinbase-stake-above-1b-snaps-up-more-uipath-shares" style="text-decoration:none">Cathie Wood, Bullish On Bitcoin, Lifts Coinbase Stake Above $1B, Snaps Up More UiPath Shares</a>
The New York-based investment firm also snapped up over 1 million shares, estimated to be worth about $29.3 in Grayscale Bitcoin Trust (OTC: <a class="ticker" href="https://www.benzinga.com/stock/gbtc#OTC">GBTC</a>), the largest Bitcoin (CRYPTO: BTC)&nbsp;fund.
GBTC shares closed 1.12% higher at $28.01 on Tuesday but have fallen about 16% since June 14.&nbsp;Bitcoin traded 4.3% higher at $34,033.74 at press time. It&#39;s down about 15% over a trailing seven-day period.
Ark deployed ARKW to buy the shares of the bitcoin fund. No other ETF holds the shares of Grayscale.&nbsp;
The investment firm holds about 8.5 million shares, worth about $238.8 million in Grayscale Bitcoin Trust.
The popular investment firm also made its fourth straight buy in&nbsp;biotechnology company&nbsp;Quantum-Si Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qsi#NASDAQ">QSI</a>), snapping up 18,700 shares, estimated to be worth about $190,553.
Another&nbsp;key Ark trade on Tuesday included selling some shares of&nbsp;Pure Storage Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>).&nbsp;
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/NUehKZBLBCQ" width="560"></iframe>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Sector ETFs

Trading Ideas

ETFs

$BTC

ARKF

ARKK

ARKW

COIN

GBTC

PSTG

TSLA

Cathie Wood Loads Up Heavily On Bitcoin Plays Coinbase, Grayscale Bitcoin Trust On Dip

Apple Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) supplier Hon Hai Precision Industry Co, Ltd (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hnhpf#OTC">HNHPF</a>), better known as Foxconn, is offering record-high cash rewards to workers ahead of the launch of iPhone 13, the South China Morning Post&nbsp;<a href="https://www.scmp.com/tech/big-tech/article/3138321/ahead-apples-iphone-13-launch-supplier-foxconn-woos-workers-record" style="text-decoration-line:none">reported</a> Tuesday.
What Happened: The rewards are being dished out by the innovative Product Enclosure Business Group (iPEBG) &mdash; the Foxconn unit which makes mechanical parts for the iPhone, as per SCMP.
See Also: <a href="https://www.benzinga.com/money/how-to-buy-apple-stock/" style="text-decoration-line:none">How To Buy Apple (AAPL) Stock</a>
Former workers returning to Foxconn&rsquo;s Zhengzhou production line for the peak season are reportedly being offered RMB 8,000 ($1,237) as a signing bonus. Last month this bonus amounted to RMB 5,500 ($848.69) and the amount was RMB 5,000 ($771.53)&nbsp;in 2020.
New iPEBG workers who are hired on the referral of an existing employee will receive RMB 7,000 ($1,080.15), while in April they were given RMB 4,500 ($694.38).&nbsp; Workers who applied by themselves will receive an RMB 7,500 ($1,157.30) bonus.
At the Taiwan-based Apple supplier&rsquo;s integrated Digital Product Business Group (iDPBG) &mdash; which assembles iPhones at Zhengzhou&nbsp;&mdash; returning workers and new referrals will get an award of RMB 600 ($92.58) for each month they stay.&nbsp;
The reward comes with a cap of RMB 5,400 ($833.26) for nine months and is on top of a monthly base salary of RMB 2,100 ($324), SCMP reported citing recruitment posts.
Why It Matters: Will Wong, a research analyst at tech research firm IDC said that the bonus pay initiatives for the Foxconn facility at Zhengzhou that employs as many as 250,000 workers indicate preparations for the new iPhone coming later this year, reported SCMP.
Foxconn purportedly raises bonus amounts for new as well as returning workers ahead of peak season when it manufactures the latest iPhones.
See Also: <a href="https://www.benzinga.com/news/21/05/21313611/apple-supplier-foxconn-eyes-stake-in-malaysian-chipmaker-to-further-ev-push-report" style="text-decoration-line:none">Apple Supplier Foxconn Eyes Stake In Malaysian Chipmaker To Further EV Push: Report</a>
This year&rsquo;s bonus for returning workers has touched the highest level since the world&rsquo;s largest iPhone manufacturing facility at Zhengzhou became operational in 2010, as per an SCMP review of past recruitment advertisements.
Foxconn&rsquo;s May revenue fell 9% on a month-on-month basis amid the&nbsp;<a href="https://www.benzinga.com/news/earnings/21/06/21444982/apple-supplier-foxconns-may-revenue-falls-amid-rising-covid-19-cases-in-taiwan-after-q1-profit-beat?utm_source=cityfalcon&amp;utm_medium=cityfalcon&amp;utm_campaign=cityfalcon" style="text-decoration-line:none">slowest monthly sales growth</a> in six months on a year-on-year basis as COVID-19 ravages Taiwan.
The Apple supplier reported revenue of $16.38 billion in May, while in April it had reported revenue of $17.83 billion.
Read Next: <a href="https://www.benzinga.com/news/21/05/21052145/iphone-12-production-sees-over-50-slump-at-apple-supplier-foxconns-factory-in-india-with-covid-19" style="text-decoration-line:none">iPhone 12 Production Sees Over 50% Slump At Apple Supplier Foxconn&#39;s Factory In India With COVID-19</a>

Retail Sales

Tech

AAPL

HNHPF

Apple Supplier Foxconn Offers Record Cash Bonuses To Workers In Bid To Ramp Up iPhone 13 Production: Report

Chinese electric vehicle maker Xpeng Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpev#NYSE">XPEV</a>) has received approval from the Hong Kong stock exchange for a dual primary listing in the city, Bloomberg <a href="https://www.bloomberg.com/news/articles/2021-06-23/ev-maker-xpeng-said-to-get-nod-for-2-billion-hong-kong-listing?sref=TBDibEcD">reported</a>&nbsp;&mdash;&nbsp;citing people with knowledge of the matter.
What Happened: Xpeng could raise as much as $2 billion from the listing in Hong Kong as soon as this year, as per the report.
Xpeng&rsquo;s listing in the Asian financial hub is a dual primary one and not a secondary listing as the company does not satisfy the two-year listing track record required for it to pursue&nbsp;a secondary listing in Hong Kong. The company went public in New York only last year.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/options/21/06/21668116/analyzing-xpengs-unusual-options-activity">Analyzing XPeng&#39;s Unusual Options Activity</a>
Why It Matters: Companies such as Xpeng, which operate in a cash-intensive industry, are seeking to raise further money without the accompanying financial burden. Xpeng, which has an SUV named G3 and a sedan named P7, <a href="https://www.benzinga.com/news/21/04/20619239/xpeng-unveils-the-p5-a-lidar-equipped-new-sedan-model-with-advanced-features-and-tech">unveiled</a> its third mass-produced electric sedan model called the P5 in April.
It was <a href="https://www.benzinga.com/tech/21/03/20270999/nio-xpeng-li-auto-hire-investment-advisors-for-hong-kong-ipo-report">reported</a> in March that the Chinese EV trio of Xpeng, Nio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nio#NYSE">NIO</a>) and Li Auto Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/li#NASDAQ">LI</a>) has hired investment advisors for their Hong Kong IPOs.
Chinese companies that are listed in the U.S. are also pursuing a listing in Hong Kong in order to expand their investor base closer to home. Additionally, it will serve to remove the overhang of a U.S. regulatory clampdown on U.S.-listed Chinese companies.
Price Action: Xpeng shares closed 8.3% lower in Tuesday&rsquo;s trading session at $39.99.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/21/06/21484017/exclusive-xpengs-brian-gu-talks-ev-competition-technology-p5-sedan-on-premarket-prep">EXCLUSIVE: XPeng&#39;s Brian Gu Talks EV Competition, Technology, P5 Sedan On &#39;PreMarket Prep&#39;</a>
Photo: Courtesy of Xpeng Motors

IPOs

Media

XPEV

Xpeng Said To Get Nod For $2B Hong Kong Listing

CNBC host Jim Cramer said Torchlight Energy Resources Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trch#NASDAQ">TRCH</a>) is a &ldquo;meme stock&rdquo; that is better because it has raised money.
What Happened: Cramer <a href="https://www.cnbc.com/2021/06/22/cramer-lightning-round-qualcomm-is-a-buy-here.html">noted</a> on CNBC&rsquo;s &ldquo;Mad Money Lightning Round&rdquo; Tuesday that Torchlight Energy had huge volume and it has raised money.
See also: <a href="https://www.benzinga.com/news/small-cap/21/06/21671785/want-to-buy-torchlight-energy-resources-trch-stock">Want to Buy Torchlight Energy Resources (TRCH) Stock?</a>
&ldquo;I am actually a believer in meme stocks that have raised money because then they&rsquo;re better,&rdquo; the television personality said.
Why It Matters: Shares of Torchlight Energy tumbled more than 29% in Tuesday&rsquo;s trading session after the oil and gas producer announced an <a href="https://www.benzinga.com/trading-ideas/short-ideas/21/06/21670344/why-torchlight-energy-shares-are-getting-hammered-today">amendment</a> to its at-the-market offering deal with Roth Capital. The offering was raised from $100 million to $250 million.
Torchlight Energy is among the companies that are seeing <a href="https://www.benzinga.com/news/21/06/21657831/wish-sees-extremely-high-wallstreetbets-interest-as-stock-surges-clean-energy-fuels-amc-blackberry-o?utm_source=cityfalcon&amp;utm_medium=cityfalcon&amp;utm_campaign=cityfalcon">high interest</a> on Reddit&rsquo;s r/WallStreetBets forum. The company&rsquo;s shares hit a new 52-week high of $10.88 on Monday after it <a href="https://www.benzinga.com/news/small-cap/21/06/21641662/why-torchlight-stock-is-blazing-higher-today">announced</a> an agreement to extend the date to close its business combination with Metamaterial Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmatf#OTC">MMATF</a>) to June 30.
Price Action: Torchlight Energy shares closed 29.4% lower in Tuesday&rsquo;s trading session at $7.00.
Read Next: <a href="https://www.benzinga.com/markets/options/21/06/21668184/unusual-options-activity-insight-torchlight-energy-res">Unusual Options Activity Insight: Torchlight Energy Res</a>

Long Ideas

Small Cap

MMATF

TRCH

Jim Cramer Says Torchlight Energy A 'Meme Stock' That's Better After Raising Money

Cathie Wood-led Ark Investment Management on Monday snapped up 35,022 shares, estimated to be worth about $7.39 million, in Alibaba Group Holding (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baba#NYSE">BABA</a>).
Shares of Alibaba closed 0.46% lower at $211.06 on Monday.
See Also: <a href="https://www.benzinga.com/fintech/21/06/21423218/alibabas-ant-secures-regulatory-approval-for-consumer-finance-firm-in-china" style="text-decoration:none">Alibaba&#39;s Ant Secures Regulatory Approval For Consumer Finance Firm In China</a>
The New York-based investment firm deployed Ark Autonomous Technology &amp; Robotics ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/arkq#BATS">ARKQ</a>) and Ark Space Exploration &amp; Innovation ETF (BATS: <a class="ticker" href="https://www.benzinga.com/stock/arkx#BATS">ARKX</a>) to buy the shares. Ark also holds shares of the Jack Ma-led company via Ark Fintech Innovation ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/arkf#NYSE">ARKF</a>).
See Also: <a href="https://www.benzinga.com/etfs/sector-etfs/21/06/21634642/cathie-wood-buys-another-6-3m-in-alibaba-rival-jd-and-sells-17m-in-netflix" style="text-decoration:none">Cathie Wood Buys Another $6.3M In Alibaba Rival JD And Sells $17M In Netflix</a>
The investment firm also snapped up 95,137 shares in Alibaba rival Pinduoduo Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pdd#NASDAQ">PDD</a>),&nbsp;estimated to be worth about $11.49 million.
Pinduoduo shares closed 3.3% lower at $120.78 on Monday.
Ark deployed ARKF to buy the shares of Pinduoduo. The investment firm also holds shares of the company via the Ark Next Generation Internet ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/arkw#NYSE">ARKW</a>).
The Shanghai-based company is known to be China&#39;s largest agriculture-based platform and had last year launched Duo Duo Grocery, a next-day grocery pickup service. Farmers list their fruits and vegetables for direct sale to consumers.
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/21/05/20833496/cathie-wood-cant-get-enough-of-these-3-chinese-alibaba-rivals" style="text-decoration:none">Cathie Wood Can&#39;t Get Enough Of These 3 Chinese Alibaba Rivals</a>
The New York-based investment firm sold 360,507 shares, estimated to be worth about $22.93 million in Snapchat parent Snap Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snap#NYSE">SNAP</a>) on the day shares of the social media company fell.
Snap shares closed 0.7% lower at $63.60 on Monday.
Wood&rsquo;s firm sold the shares in Snap via ARKF and also holds shares of the social media company via ARKW.
See Also: <a href="https://www.benzinga.com/etfs/sector-etfs/21/06/21485239/cathie-wood-sells-snapchat-docusign-for-second-straight-day-buys-spotify" style="text-decoration:none">Cathie Wood Sells Snapchat, DocuSign For Second Straight Day, Buys Spotify</a>
The popular investment firm&nbsp;sold 321,235 shares, estimated to be worth about $22.85 million, in the social media company Pinterest Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pins#NYSE">PINS</a>).
Pinterest shares closed 4% lower at $71.14 on Monday. Ark sold the shares of the social media company via ARKF, no other ETF holds shares of the company.
Some of the other key Ark sells on Monday include NXP Semiconductors NV (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpi#NASDAQ">NXPI</a>) and buys include Roblox Corp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rblx#NYSE">RBLX</a>)
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/NUehKZBLBCQ" width="560"></iframe>

Short Ideas

ARKQ

ARKX

BABA

NXPI

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PINS

RBLX

SNAP

TDOC

Cathie Wood Piles Up Shares In Alibaba, Rival Pinduoduo, Trims Snapchat, Pinterest

Microsoft Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) joined Apple Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) as the second U.S. company to achieve a $2 trillion valuation on Tuesday.
What Happened: Microsoft shares touched an intraday high of $265.79 in Tuesday&rsquo;s trading giving the company a valuation slightly above&nbsp;$2 trillion.
In August last year, Apple&rsquo;s market cap <a href="https://www.benzinga.com/amp/content/17176566" style="text-decoration-line:none">rose beyond the $2 trillion mark</a>. At the time, some analysts said that the Tim Cook-led tech giant is on its way to the $3 trillion level.
Cloud has been a key driver in the recent spurt of growth for Microsoft,&nbsp;with total revenue from that segment hitting <a href="https://www.benzinga.com/news/earnings/21/04/20823950/microsoft-beats-q3-earnings-estimates-sees-azure-revenue-up-50" style="text-decoration-line:none">$17.7 billion in the third quarter</a>, which translates into a growth of 33% year-over-year.
As per Q3 results, the company&rsquo;s intelligent cloud segment revenue stood at $15.1 billion, a growth of 23% year-over-year.
Microsoft also saw robust growth in its cloud service revenue which shot up 26% year-over-year buoyed by Azure revenue which shot up 50% year-over-year.&nbsp;
Why It Matters: Year-to-date returns on Microsoft shares have eclipsed other tech giants such as cloud rival Amazon.com, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) and even Apple.&nbsp;
MSFT shares have spiked 19.4% since 2021 began, while Amazon and Apple shares rose 7.6% and 1%, respectively.&nbsp;
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/03/20181711/from-amazon-towards-microsoft-why-tide-is-shifting-in-the-cloud-arms-race" style="text-decoration-line:none">From Amazon Towards Microsoft &mdash; Why &#39;Tide Is Shifting In The Cloud Arms Race&#39;</a>
&quot;Another solid quarter across Microsoft&#39;s major lines of business underscores powerful DX tailwinds and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/04/20841686/4-microsoft-analysts-break-down-software-giants-q3-earnings-cloud-strength-long-ter" style="text-decoration-line:none">solid execution in place</a> across key components of the Microsoft cloud,&rdquo; said Bank of America analyst Brad Sills, post the company&rsquo;s Q3 results.
Price Action: On Tuesday, Microsoft shares closed 1.1% higher at $265.51 in the regular session and gained another almost 0.2% in the after-hours trading.
Read Next: <a href="https://www.benzinga.com/news/21/05/21144985/why-did-bill-gates-leave-microsoft-board-reportedly-a-probe-into-a-prior-affair?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29" style="text-decoration-line:none">Why Did Bill Gates Leave Microsoft Board? Reportedly, A Probe Into A Prior Affair</a>

AMZN

MSFT

Microsoft Joins Apple In The $2T Valuation Club

Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk made an appearance on &ldquo;Saturday Night Live&rdquo; on May 8 in an episode that was expected to feature Dogecoin (CRYPTO: DOGE) heavily.
See Also: <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge/" style="text-decoration-line:none">How To Buy Dogecoin (DOGE)&nbsp;</a>
Musk did not disappoint, mentioning the meme coin during his opening monologue. The Tesla CEO&nbsp;also appeared as a financial expert during a skit and <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21026043/heres-the-elon-musk-dogecoin-bit-on-snl-everyone-is-talking-about" style="text-decoration-line:none">called DOGE a &ldquo;hustle.&rdquo;</a>
DOGE Investment: If an investor got inspired to invest $1,000 in DOGE on the day Musk appeared on &ldquo;Saturday Night Live,&rdquo; here is how much they would have today.
See Also: <a href="https://www.benzinga.com/news/21/06/21672468/heres-why-elon-musk-wont-win-an-emmy-for-snl-hosting-gig" style="text-decoration-line:none">Here&#39;s Why Elon Musk Won&#39;t Win An Emmy For &#39;SNL&#39; Hosting Gig</a>
Investing $1,000 in Dogecoin at its intraday peak of $0.74 would have secured 1,351.35 DOGE for the investors.
This is also the all-time high level for the Shiba Inu-themed cryptocurrency, which is now trading 71.14% below those highs at $0.215.
DOGE traded 5.03% higher over 24 hours leading up to press time.
At the current price, the $1,000 investment made on the day Saturday Night Live featuring Musk aired would only be worth $290.54.
Doggone Returns: The $1,000 investment translated into a 70.94% loss for the investor, but it is worth keeping in mind that DOGE has returned 4,306.31% gains since the year began.
The meme cryptocurrency has a market cap of $27.70 billion, making it the seventh currency in terms of market capitalization, as per CoinMarketCap data.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21638486/dogecoin-as-an-asset-accurately-reflects-current-economic-climate-says-ftx-ceo" style="text-decoration-line:none">Dogecoin As An Asset &#39;Accurately Reflects&#39; Current Economic Climate, Says FTX CEO</a>
Photo: Screenshot of &quot;Lloyd Ostertag&quot; on &quot;Weekend Update&quot; as he says &quot;To the moooon!&quot;

Education

General

$DOGE

If You Invested $1,000 In Dogecoin When Elon Musk Made His SNL Appearance, Here's How Much You Would Have Now

ContextLogic Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wish#NASDAQ">WISH</a>), Clover Health Investments Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clov#NASDAQ">CLOV</a>) and BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) are seeing the highest interest on Reddit&rsquo;s r/WallStreetBets forum.
What Happened: ContextLogic, an e-commerce company that operates the Wish platform, continued to be the most-discussed stock on the forum with 1,423 mentions during the last 24 hours at press time, data from Quiver Quantitative showed.
Medical insurance technology company Clover Health was a distant second with 878 mentions, followed by Canada-based tech giant BlackBerry with 732 mentions. BlackBerry is set to announce its first-quarter earnings after the bell on Thursday.
The other stocks that are trending on the forum include movie theatre chain AMC Entertainment Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amc#NYSE">AMC</a>), videogame retailer GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>), renewable natural gas company Clean Energy Fuels Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clne#NASDAQ">CLNE</a>) and exchange-traded fund SPDR S&amp;P 500 ETF Trust (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>).
Satellite communications company Globalstar Inc.(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gsat#NYSE">GSAT</a>) and retailer Big Lots Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/big#NYSE">BIG</a>) are among the new stocks that are seeing high interest on the forum.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/long-ideas/21/06/21668609/why-wish-stock-looks-to-break-out">Why WISH Stock Looks To Break Out</a>
Why It Matters: ContextLogic continues to be a favorite with retail investors due to its high level of institutional ownership and the amount of short interest on the stock.
Clover Health is seeing renewed interest after the company acknowledged in a regulatory filing&nbsp;that the recent momentum in its stock could be the result of a short squeeze.
Globalstar shares rose after B. Riley <a href="https://www.benzinga.com/markets/penny-stocks/21/06/21670392/why-globalstar-is-trading-higher-again-today">initiated</a> coverage on the company and announced a price target well above its current level.
Price Action: ContextLogic shares closed unchanged in Tuesday&rsquo;s regular trading session at $13.50, but rose almost 1.9% in the after-hours session to $13.75.
Clover Health shares closed almost 12.4% higher in the regular trading session at $12.63 and further rose almost 1.4% in the after-hours session to $12.80.
BlackBerry shares closed almost 4.8% higher in the regular trading session at $13.41, but declined 0.6% in the after-hours session to $13.33.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/21/06/21658321/jim-cramer-continues-the-ape-tease-surprised-memesters-having-such-a-hard-time-propping-up-amc">Jim Cramer Continues The Ape-Tease: Surprised &#39;Memesters Having Such A Hard Time Propping Up AMC&#39;</a>

Penny Stocks

CLNE

CLOV

GSAT

WISH

Wish Remains Top WallStreetBets Interest, Alongside Clover Health, BlackBerry, AMC

Famed Dogecoin (CRYPTO: DOGE) investor Glauber Contessoto has refused to sell his holdings in the meme cryptocurrency despite losing his millionaire status following the selloff in the cryptocurrency market earlier in the week.
What Happened: Contessoto, who invested his life savings in Dogecoin earlier this year, <a href="https://www.cnbc.com/2021/06/22/millennial-dogecoin-investor-refuses-to-sell-despite-crypto-crash.html">told</a> CNBC that while he is not currently a &ldquo;dogecoin millionaire&rdquo; on paper, he plans to hold the currency for more than a year.
&ldquo;Whatever happens in the short-term doesn&rsquo;t matter to me because I&rsquo;m looking to &lsquo;hodl&rsquo; dogecoin for years to come. I&rsquo;m truly not worried at the end of the day,&rdquo; Contessoto said.
See Also: <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge/">How To Buy Dogecoin (DOGE)</a>
He added he would have been worried if apex cryptocurrency&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/">Bitcoin</a> (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) were also not hit.
Contessoto&rsquo;s Dogecoin holdings touched <a href="https://www.benzinga.com/markets/cryptocurrency/21/05/21140821/meet-the-dogecoin-millionaire-whos-holding-onto-his-bag">$2 million</a> in May after the Shiba Inu-themed cryptocurrency hit an all-time high of almost 74 cents in early May. However, his portfolio was worth only $831,539 as of Tuesday evening following the bloodbath in the cryptocurrency market, as per the CNBC report.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21658609/why-is-dogecoin-in-such-a-slumber-right-now">Why Is Dogecoin In Such A Slumber Right Now?</a>
Why It Matters: Dogecoin has shot to prominence this year, buoyed by endorsements from Tesla Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk and other celebrities. However, the meme cryptocurrency is down almost 71.5% from the all-time high of $0.7376 it touched in May.
Bitcoin and other cryptocurrencies plunged Monday after China&rsquo;s central bank <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21658127/why-is-bitcoin-tanking-today">warned</a> financial institutions against dealing with cryptocurrency-related services. The cryptocurrency market is showing signs of a <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21677585/dogecoin-surges-8-as-wider-cryptocurrency-market-shows-slight-recovery">slight recovery</a> as of Tuesday night.
Price Action: Dogecoin is up more than 7%&nbsp;during the last 24 hours, trading at $0.2162 at press time.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/21/06/21638193/dogecoin-headed-to-5-cents-after-losing-crucial-support-level-and-even-elon-musk-ca">Dogecoin Headed To 5 Cents After Losing Crucial Support Level And Even Elon Musk Can&#39;t Save It, Says Bitcoin Bull</a>

$ETH

Diamond Hands? Famed Dogecoin Investor Says Not Selling Despite Losing Millionaire Status

<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/" style="text-decoration-line:none">Bitcoin</a> (CRYPTO: BTC) traded above the $33,000 level on Tuesday night after touching a low of $28,893.62 on an intraday basis. Analysts are of the view that the apex cryptocurrency may have more pain in store for investors as it may not have found a bottom around the $29,000 mark.
Looming Summer Of Discontent: The <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21657974/dogecoin-tanks-28-in-massive-crypto-rout-ethereum-falls-below-2-000-mark" style="text-decoration-line:none">recent turmoil</a> in the cryptocurrency market was fueled by China and its crackdown on Bitcoin miners. Additional pressures came in from Grayscale unlocking schedule and selling by newcomers, as per ExoAlpha partner &Eacute;lie Le Rest, <a href="https://cointelegraph.com/news/bitcoin-price-bounces-to-33k-but-analysts-say-it-s-too-early-to-call-a-bottom" style="text-decoration-line:none">reported</a> Cointelegraph.
See Also: <a href="https://www.benzinga.com/money/how-to-buy-bitcoin/" style="text-decoration-line:none">How To Buy Bitcoin (BTC)</a>
La Rest theorized that Bitcoin prices could be rangebound between $25,000 to $35,000 in July and low volumes in August holding potential to &ldquo;accelerate this downside trend or build the upside trend.&rdquo;
Institutional Caprice: Total open interest in the BTC futures market stands at $11.3 billion, a decline of 59% from the April 13 peak of $27.3 billion, as per Arcane Research data, <a href="https://www.coindesk.com/open-interest-in-bitcoin-futures-drops" style="text-decoration-line:none">reported</a> CoinDesk.
The report by Arcane said that institutional investors are being &ldquo;cautious&rdquo; at the moment and noted that the three-month futures in BTC are in backwardation &mdash; which means they are being traded at a discount to current spot prices, as per CoinDesk.
Open interest on the Chicago Mercantile Exchange (CME) is currently at 12.2% of the Bitcoin futures market, as per Arcane. Open interest on the CME as a share of the total bitcoin futures was rising at the end of May but now has taken a downwards turn.
Paging Mr. Musk: David Lifchitz, the chief investment officer of ExoAlpha, said that BTC seems to have drawn &ldquo;the line in sand&rdquo; at $29,000 and Ethereum (CRYPTO: ETH) at $1,700, but even he warns against abandoning prudence but did playfully call out for the intervention of Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) CEO Elon Musk.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21638137/you-can-now-buy-bitcoin-dogecoin-ethereum-alongside-apples-oranges-at-h-e-bs-houston-store" style="text-decoration-line:none">You Can Now Buy Bitcoin, Dogecoin, Ethereum Alongside Apples, Oranges At H-E-B&#39;s Houston Stores</a>
&ldquo;It&#39;s too early to tell if this is &#39;the&#39; bottom or just a temporary floor before more downside. The lack of any upside catalyst (besides some contrarian oversold metrics) remains the biggest hurdle for cryptos to bounce back... Paging Mr.Musk, paging Mr.Musk,&rdquo; said Lifchitz, as per Cointelegraph.
BTC traded 3.78% higher at $33,812.33 at press time over 24 hours, while ETH traded 2.43% higher at $1,996.72.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21638486/dogecoin-as-an-asset-accurately-reflects-current-economic-climate-says-ftx-ceo" style="text-decoration-line:none">Dogecoin As An Asset &#39;Accurately Reflects&#39; Current Economic Climate, Says FTX CEO</a>

Has Bitcoin Found The Bottom At $29,000?

Amazon.com Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) has consolidated its position as the world&rsquo;s most valuable brand in 2021, followed by Apple Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>), according to a global ranking released by Kantar&rsquo;s BrandZ.
What Happened: The e-commerce company remained the world&rsquo;s most valuable brand with 64% growth in its brand value to $683.9 billion, while Cupertino-based tech giant Apple was valued at $612 billion. In the process, Amazon and Apple became the first half-a-trillion-dollar brands.
The brand value of Alphabet&nbsp; Inc.&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>) (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) unit Google was pegged at $458 billion, while Microsoft Corp.&rsquo;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) brand value was estimated at $410.3 billion.
Chinese brands are making their presence increasingly felt, having grown from 11% of the Top 100 value in 2011 to 14% today, as per the report. Tencent Holding Ltd. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/tcehy#OTC">TCEHY</a>) was ranked as the world&rsquo;s fifth most valuable brand, while Chinese e-commerce giant Alibaba Group Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/baba#NYSE">BABA</a>) claimed the seventh position.
Electric vehicle maker Tesla Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) is the fastest-growing brand and also became the most valuable car brand following a 275% year-on-year growth in its value to $42.6 billion, the report noted.
See Also: <a href="https://www.benzinga.com/news/21/06/21629296/as-amazon-readies-for-prime-day-rival-retailers-prepare-their-own-sales-events">As Amazon Readies For Prime Day, Rival Retailers Prepare Their Own Sales Events</a>
Why It Matters: The report showed that technology brands continue to dominate the top of the rankings, with seven of the top ten brands from the tech sector.
The total value of the 100 most valuable global brands has grown by 42%, to more than $7 trillion, indicating that these brands have significantly rebounded from the economic impact of the global pandemic.
In particular, Amazon has benefited from amid increased demand for its core services amid the pandemic, including in the e-commerce, cloud, and streaming video-on-demand sectors.
Price Action: Amazon shares closed 0.9% lower in Monday&rsquo;s trading session at $3453.96, while Apple shares closed 1.4% higher at $132.30.
Read Next: <a href="https://www.benzinga.com/news/21/06/21626927/apple-could-take-50-bite-out-of-intels-business-in-2021-report">Apple Could Take 50% Bite Out Of Intel&#39;s Business In 2021: Report</a>

Events

GOOG

GOOGL

TCEHY

Amazon World's Most Valuable Brand Followed By Apple, Kantar Finds

Some shades of green returned to the battered cryptocurrency market on Tuesday night with meme-based Dogecoin (CRYPTO: DOGE) registering near 8% gains.
What Happened: DOGE traded 7.93% higher at $0.19 at press time over 24 hours. The Shiba Inu-themed cryptocurrency still traded 40.87% lower over a seven-day period.
See Also: <a href="https://www.benzinga.com/money/how-to-buy-dogecoin-doge/" style="text-decoration-line:none">How To Buy Dogecoin (DOGE)</a>
DOGE scored 3.42% and 8.79% gains against <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment/" style="text-decoration-line:none">Bitcoin</a> (CRYPTO: BTC) and Ethereum (CRYPTO: ETH), the two top cryptocurrencies by market capitalization.
BTC traded 4.01% higher at $32,801.62 over 24 hours, while ETH traded 0.25% lower at $1,894.42 in the same period.
BTC and ETH declined 17% and 24.94% respectively over a week leading up to press time.
Other cryptocurrencies that saw significant gains included Celo (CRYPTO: CELO), which traded 25.31% higher at $2.30 at press time over 24 hours. Chiliz (CRYPTO: CHZ) traded 9.3% higher at $0.23 in the same period.
The top gainer on Tuesday evening was Livepeer (CRYPTO: LPT), the token of a decentralized live video streaming network, which soared 28.18% to $24.74. The cryptocurrency rose 23.72% and 30.13% against BTC and ETH, respectively.
Why It Matters: Mason Nystrom, a research analyst at Messari, said on Twitter Monday that Livepeer is finding product-market-fit and is transcoding a million minutes of video each week. 
&nbsp;
<blockquote class="twitter-tweet">Web3 infrastructure protocols are unbundling the existing internet services at an accelerated rate.
Livepeer - a marketplace for video streaming services &ndash; is finding product-market-fit and currently facilitating the transcoding of a million minutes of video each week. <a href="https://t.co/P41QeOfEcA">pic.twitter.com/P41QeOfEcA</a>
&mdash; Mason Nystrom (@masonnystrom) <a href="https://twitter.com/masonnystrom/status/1407319774833618950?ref_src=twsrc%5Etfw">June 22, 2021</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Meanwhile, the cryptocurrency market is seeing the return of some gains after a bloodbath earlier in the week.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21638486/dogecoin-as-an-asset-accurately-reflects-current-economic-climate-says-ftx-ceo" style="text-decoration-line:none">Dogecoin As An Asset &#39;Accurately Reflects&#39; Current Economic Climate, Says FTX CEO</a>
As of press time, global cryptocurrency market capitalization touched $1.28 trillion, a gain of 2.04% over 24 hours.
Bitcoin and other cryptocurrencies plunged Monday after China&rsquo;s central bank instructed the country&rsquo;s major <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21658127/why-is-bitcoin-tanking-today" style="text-decoration-line:none">financial institutions to restrict services</a> for cryptocurrency transactions.
The People&rsquo;s Bank of China action comes after an <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21635080/chinas-cryptocurrency-mining-crackdown-intensifies-spreads-to-sichuan" style="text-decoration-line:none">earlier crackdown</a> on mining operations by authorities in China&rsquo;s Sichuan province.
A major Chinese miner has said that it has moved its <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21666430/chinese-bitcoin-miners-have-already-shipped-equipment-to-kazakhstan-report-shows">rigs to Kazakhstan</a> after its power supply was snapped by a Sichuan utility.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21657844/exclusive-in-bid-to-expand-bitcoin-ecosystem-stacks-funds-25-startups-building-user-owned-" style="text-decoration-line:none">EXCLUSIVE: In Bid To Expand Bitcoin Ecosystem, Stacks Funds 25 Startups Building &#39;User-Owned Internet&#39;</a>
Photo by&nbsp;<a href="https://unsplash.com/@executium?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Executium</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/dogecoin?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

Movers

Dogecoin Surges 8% As Wider Cryptocurrency Market Shows Slight Recovery

<img alt="Fintech Header" src="https://cdn2.hubspot.net/hub/2786381/hubfs/Fintech%20Header.png?upscale=true&amp;width=800&amp;upscale=true&amp;name=Fintech%20Header.png" />
Quote To Start The Day: &ldquo;Amazon is the most formidable. If Amazon can get you lower-debt payments or give you a bank account, you&rsquo;ll buy more stuff on Amazon.&rdquo;
Source: <a href="https://www.cbinsights.com/research/report/amazon-across-financial-services-fintech/?utm_source=CB%20Insights%20Newsletter&amp;utm_campaign=f3cdeea6cb-newsletter_general_Tues_20210622&amp;utm_medium=email&amp;utm_term=0_9dc0513989-f3cdeea6cb-87539605&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">Alex Rampell</a>
One Big Thing In Fintech: While headlines from the blockchain industry have recently been dominated by Bitcoin, the biggest story in the space has still largely been overlooked (or missed) by most news outlets: the rise of DeFi, or Decentralized Finance.
Over the last year, a &ldquo;decentralized Wall Street&rdquo; has emerged, with users locking up over $50 billion worth of assets into applications that are replicating traditional financial products on decentralized blockchain infrastructure.
Source: <a href="https://www.nasdaq.com/articles/defi-is-ready-to-disrupt-fintech-2021-06-22?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">Nasdaq</a>
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/giphy-Jun-23-2021-12-08-00-46-AM.gif?upscale=true&amp;width=800&amp;upscale=true&amp;name=giphy-Jun-23-2021-12-08-00-46-AM.gif" />
Other Key Fintech Developments:
<ul>
<li>Liti Capital <a href="https://www.digitaljournal.com/pr/liti-capital-announces-dual-token-launch-to-fight-crypto-criminals?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">announces</a> token launch.</li>
<li>Deutsche, Fiserv have <a href="https://www.bankingdive.com/news/deutsche-bank-fiserv-team-up-in-german-market/602222/?utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Issue%3A%202021-06-22%20Banking%20Dive%20%5Bissue%3A34971%5D&amp;utm_term=Banking%20Dive&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">partnered</a> up.</li>
<li>The battle <a href="https://fortune.com/2021/06/22/the-battle-forming-in-the-european-fintech-scene/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">rising</a> in European fintech.</li>
<li>Toss <a href="https://www.bloomberg.com/news/articles/2021-06-22/a-7-billion-fintech-super-app-eyes-12-fold-growth-ipo-by-2025?sref=TBDibEcD&amp;utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">secured</a> $406M at $7.4B value.</li>
<li>Rewards <a href="https://techcrunch.com/2021/06/22/a-rewards-program-for-your-rent-payments-meet-bilt/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">program</a> for rent payments.</li>
<li>TrueLayer <a href="https://fintechmagazine.com/banking/truelayer-launches-new-verification-api?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">launches</a> verification API.</li>
<li>MAJORITY <a href="https://finledger.com/2021/06/22/immigrant-digital-banking-provider-majority-raises-19m-seed-round/?utm_campaign=Newsletter%20-%20Daily&amp;utm_medium=email&amp;_hsmi=135513496&amp;utm_content=135513496&amp;utm_source=hs_email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">raises</a> $19M seed round.</li>
<li>Fifth Third <a href="https://www.businesswire.com/news/home/20210622005706/en/Fifth-Third-Announces-Acquisition-of-Provide-a-Fintech-Company-Serving-Healthcare-Practices-Nationally?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">acquires</a> fintech Provide.</li>
<li>TT <a href="https://www.tradingtechnologies.com/news-releases/trading-technologies-launches-support-for-cboe-u-s-options-and-plans-day-one-connectivity-to-cboe-europe-derivatives-via-the-tt-platform/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">adds</a> Cboe trading functionalities.</li>
<li>Fundbox <a href="https://www.globenewswire.com/news-release/2021/06/22/2251250/0/en/Fundbox-Appoints-Hilliard-Terry-to-Board-of-Directors.html?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">added</a> to board of directors.</li>
<li>Tabby <a href="https://www.bloomberg.com/news/articles/2021-06-21/mubadala-backed-dubai-fintech-startup-loads-up-on-debt-financing?sref=TBDibEcD&amp;utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">taps</a> $50M financing to grow.</li>
<li>Myos <a href="https://www.finextra.com/pressarticle/88215/retailer-finance-startup-myos-raises-30-million?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">raises</a> $30M Series A funding.</li>
<li>Moneycorp <a href="https://www.finextra.com/pressarticle/88221/moneycorp-americas-unveils-enhanced-api-integration?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">unveils</a> enhanced APIs.</li>
<li>Blockchain Capital <a href="https://stockhouse.com/news/press-releases/2021/06/22/blockchain-capital-raises-300-million-for-fund-v?utm_content=article-5843&amp;utm_campaign=article_email&amp;utm_source=sg&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">added</a> new funds.</li>
<li>Zeller <a href="https://techcrunch.com/2021/06/22/australian-fintech-zeller-lands-50m-aud-led-by-spark-capital-at-a-400m-aud-valuation/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">lands</a> $50M AUD led by Spark.</li>
<li>Tradefeedr <a href="https://www.thetradenews.com/tradefeedr-launches-fx-trading-database/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">adds</a> FX trading database.</li>
<li>Mollie <a href="https://finledger.com/2021/06/22/payment-integration-company-mollie-raises-800-million-round/?utm_campaign=Newsletter%20-%20Daily&amp;utm_medium=email&amp;_hsmi=135513496&amp;utm_content=135513496&amp;utm_source=hs_email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">secured</a> $800M for payments.</li>
<li>Bueno Finance <a href="https://economictimes.indiatimes.com/tech/funding/fintech-startup-bueno-finance-raises-3-million-as-seed-funding/articleshow/83741533.cms?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">secured</a> $3M funding.</li>
<li>Magma <a href="https://www.businesswire.com/news/home/20210622005251/en/Magma-Capital-Funds-Launches-Obsidian-a-Quant-Driven-Investment-Fund-for-Professional-Athletes?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">added</a> Obsidian quant fund.</li>
<li>Egypt laws will <a href="https://www.reuters.com/business/egypt-eyes-surge-fintech-investment-after-new-laws-2021-06-22/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">spark</a> fintech growth.</li>
<li>Nonbank lenders <a href="https://www.wsj.com/articles/nonbank-lenders-are-dominating-the-mortgage-market-11624367460?mod=hp_lista_pos1&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Issue%3A%202021-06-22%20Banking%20Dive%20%5Bissue%3A34971%5D&amp;utm_term=Banking%20Dive&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">tackled</a> mortgages.</li>
<li>Banks, credit unions <a href="https://www.americanbanker.com/news/regional-banks-credit-unions-begin-lending-to-pot-firms?position=editorial_3&amp;campaignname=AB%20Daily%20Briefing-06222021&amp;utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=AB_Daily_Daily_Briefing_Lite_RELAUNCH-06222021&amp;bt_ee=kYSYoXDLKPQLG9lcMkJvJZEbTHzmyFnAuUIrVv0jxGnVaJG%2BttJzZYxnlzVx1z7a&amp;bt_ts=1624366873867&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">lend</a> to pot firms.</li>
<li>CommerceIQ <a href="https://www.finextra.com/pressarticle/88214/commerceiq-closes-60-million-series-c?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">closes</a> $60M Series C.</li>
<li>State Street, Canoe have <a href="https://www.businesswire.com/news/home/20210622005654/en/State-Street-Leverages-Machine-Learning-to-Streamline-Private-Markets-Processing-and-Document-Management-Through-Partnership-with-Canoe-Intelligence?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">partnered</a>.</li>
<li>JPMorgan <a href="https://www.businessinsider.com/jpmorgan-research-investment-bank-future-trading-technology-fintech-competition-2021-6?nr_email_referer=1&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_content=Business_Insi&amp;utm_campaign=Issue%3A%202021-06-22%20Banking%20Dive%20%5Bissue%3A34971%5D&amp;utm_term=Banking%20Dive&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">outlines</a> visions for future.</li>
<li><a href="https://www.cbinsights.com/research/report/amazon-across-financial-services-fintech/?utm_source=CB%20Insights%20Newsletter&amp;utm_campaign=f3cdeea6cb-newsletter_general_Tues_20210622&amp;utm_medium=email&amp;utm_term=0_9dc0513989-f3cdeea6cb-87539605&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">Unpacking</a> Amazon&rsquo;s fintech visions.</li>
<li>Discover <a href="https://www.bankingdive.com/news/discover-makes-a-crypto-move-with-new-hire/602079/?utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Issue%3A%202021-06-22%20Banking%20Dive%20%5Bissue%3A34971%5D&amp;utm_term=Banking%20Dive&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">moves</a> into crypto with hire.</li>
<li>Third Point <a href="https://www.coindesk.com/loebs-third-point-leads-27m-investment-in-crypto-compliance-startup-ciphertrace?utm_content=article-5843&amp;utm_campaign=article_email&amp;utm_source=sg&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">leads</a> CipherTrace round.</li>
<li>NCR is <a href="https://finance.yahoo.com/amphtml/news/ncr-corporation-industry-leader-multi-120000666.html?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">reinventing</a> ATM technology.</li>
<li>Rivalry <a href="https://www.globenewswire.com/news-release/2021/06/22/2250914/0/en/Leading-Esports-Sportsbook-and-Media-Company-Rivalry-Closes-Oversubscribed-US-22-Million-Subscription-Receipt-Financing.html?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy#:~:text=TORONTO%2C%20June%2022%2C%202021%20(,financing%20for%20gross%20proceeds%20of">secured</a> $22M funding round.</li>
<li>Sporttrade <a href="https://www.prnewswire.com/news-releases/sporttrade-inc-raises-36-million-to-transform-sports-betting-301316520.html?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">secured</a> $36M for betting.</li>
</ul>
Watch Out For This: With consumption habits of younger and older Americans moving in opposite directions, advertisers and media companies will likely need a clear understanding of their target audiences in order to be successful.
Source: <a href="https://www.visualcapitalist.com/how-media-consumption-evolved-throughout-covid-19/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">Visual Capitalist</a> 
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/Knight-Foundation-1200px-1.jpeg?upscale=true&amp;width=800&amp;upscale=true&amp;name=Knight-Foundation-1200px-1.jpeg" />
Interesting Reads:
<ul>
<li>Delta variant <a href="https://www.bloomberg.com/news/articles/2021-06-21/delta-variant-seen-spreading-in-undervaccinated-u-s-counties?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">gaining</a> across the US.</li>
<li>Canadians looking to <a href="https://www.bloomberg.com/news/articles/2021-06-22/trudeau-s-party-passes-bill-to-regulate-social-media-streaming?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">regulate</a> media.</li>
<li>Oil could <a href="https://www.bloomberg.com/news/articles/2021-06-22/trafigura-says-oil-could-hit-100-a-barrel-next-year?utm_campaign=socialflow-organic&amp;utm_content=markets&amp;utm_source=twitter&amp;cmpid%3D=socialflow-twitter-markets&amp;utm_medium=social&amp;sref=TBDibEcD&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">reach</a> $100/barrel next year.</li>
<li>Is inflation or deflation the bigger <a href="https://ark-invest.com/newsletters/issue-275/?utm_content=170207235&amp;utm_medium=social&amp;utm_source=twitter&amp;hss_channel=tw-2398137084&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">risk</a>?</li>
<li>Automation <a href="https://ark-invest.com/articles/analyst-research/will-automation-cause-an-increase-in-the-unemployment-rate/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">increase</a> unemployment?</li>
<li>Morgan Stanley <a href="https://www.bloomberg.com/news/articles/2021-06-22/morgan-stanley-tells-staff-they-ll-need-vaccines-to-enter-office?srnd=premium&amp;utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">requires</a> vaccination.</li>
<li><a href="https://news.crunchbase.com/news/heres-which-vc-backed-companies-are-going-public-via-spac-this-year-so-far/?utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">Which</a> VC-backed SPACs will come?</li>
</ul>
Market Moving Headline: Federal Reserve Chair Jerome Powell said the price increases seen in the economy recently are bigger than expected but reiterated that they will likely wane.
Source: <a href="https://www.bloomberg.com/news/articles/2021-06-22/powell-says-inflation-from-reopening-larger-than-expected?srnd=premium&amp;sref=TBDibEcD&amp;utm_campaign=Fintech%20-%20BZ%20Fintech%20Daily%20Beat&amp;utm_source=hs_email&amp;utm_medium=email&amp;_hsenc=p2ANqtz-8jr-BYc9UoSf0UwFtTWp1wwnoaqldgY8CZQYxv_HRTqwluM8JNP7nKKlJp7kYK8cH6bFfy">Bloomberg</a>
<img src="https://cdn2.hubspot.net/hub/2786381/hubfs/giphy%20(1)-Jun-23-2021-12-08-04-57-AM.gif?upscale=true&amp;width=800&amp;upscale=true&amp;name=giphy%20(1)-Jun-23-2021-12-08-04-57-AM.gif" />

Fintech news covering the emerging Financial Technology services sector

Fintech

Fintech Focus For June 23, 2021

What Happened: Shenzhen-based Bitcoin miner BIT Mining (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/btcm#NYSE">BTCM</a>) has already shipped some of its mining equipment outside China, according to a <a href="https://ir.btc.com/2021-06-21-BIT-Mining-Successfully-Delivers-Mining-Machines-to-Kazakhstan" style="color:#0563c1; text-decoration:underline">press release</a> from the company.
The company reported that 320 mining machines with a capacity of 18.2 PH/s had&nbsp;been delivered to a facility in Kazakhstan, which is expected to be fully operational by June 27.
A second and third batch, totaling 2,600 mining machines with a theoretical maximum total hash rate capacity of 102.3 PH/s, are also expected to be delivered to&nbsp;Kazakhstan&nbsp;before&nbsp;July 1, 202.
Why It Matters: The company&rsquo;s overseas deployment strategy was put into effect after it received a notice from the State Grid Sichuan Ganzi Electric Power supplier notifying them that the power supply would be suspended on June 19.
BIT Mining&rsquo;s Chinese subsidiary was one of the <a href="https://www.benzinga.com/markets/cryptocurrency/21/06/21635080/chinas-cryptocurrency-mining-crackdown-intensifies-spreads-to-sichuan" style="color:#0563c1; text-decoration:underline">26 Bitcoin miners</a> that were forcibly shut down by local authorities on Sunday&nbsp;after a government crackdown on crypto mining and trading in the region further intensified.
&quot;We are committed to protecting the environment and lowering our carbon footprint. We have been strategically expanding our operations overseas as part of our growth strategy,&rdquo; commented&nbsp;Xianfeng Yang,&nbsp;CEO of BIT Mining.
&ldquo;Following our investments in cryptocurrency mining data centers in&nbsp;Texas&nbsp;and&nbsp;Kazakhstan, we are accelerating our overseas development for alternative high-quality mining resources,&rdquo; he added.
According to a report from <a href="https://www.washingtonpost.com/world/asia_pacific/bitcoin-mining-china-crypto-america/2021/06/17/0a39c3a8-c903-11eb-8708-64991f2acf28_story.html" style="color:#0563c1; text-decoration:underline">The Washington Post</a>, Chinese miners are now focused on expanding to other geographies, including the U.S.
&ldquo;Right now in China, everybody&rsquo;s scared. The question is not whether you pull out, but immediately or gradually,&rdquo; said one miner under the condition of anonymity.
Price Action: Bitcoin was trading at $32,418&nbsp;at the time of writing, up 1,81% from its earlier dip below $30,000.&nbsp;

Government

Global

BTCM

Chinese Bitcoin Miners Have Already Shipped Equipment To Kazakhstan, Report Shows

Many investors like the allure of small cap stocks. Buying the next Apple Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) or Amazon.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amzn#NASDAQ">AMZN</a>) while they&#39;re still in their infancy is every investor&rsquo;s dream.
But investing in small cap stocks can be difficult. Many of them aren&rsquo;t covered by the Wall Street investment firms so it&rsquo;s hard to find research and opinions on them.
Investors who are seeking exposure to this part of the investment universe but don&rsquo;t want the risk of owning individual stocks should consider ETFs. These include the iShares Micro-Cap ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iwc#NYSE">IWC</a>) and the iShares Russell 2000 ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iwm#NYSE">IWM</a>).
IWC tracks the Russell Microcap Index. It invests in companies that have a market cap between $50 million and $300 million.
<img alt="iwc.png" src="https://www.benzinga.com/files/u344550/iwc.png" style="height:400px; width:640px" />
IWM tracks the Russell 2000 index. It invests in companies that have a market cap between $300 million and $2 billion.
<img alt="iwm.png" src="https://www.benzinga.com/files/u344550/iwm.png" style="height:400px; width:640px" />

Specialty ETFs

Small Cap Analysis

2 ETFs For Small And Microcap Investors

Carl Nassib <a href="https://www.benzinga.com/news/21/06/21658228/raiders-carl-nassib-becomes-first-active-nfl-player-to-be-openly-gayhttps://www.benzinga.com/news/21/06/21658228/raiders-carl-nassib-becomes-first-active-nfl-player-to-be-openly-gay">made headlines </a>Monday after being the first active NFL player to come out as gay. The Las Vegas Raiders defensive end is also being remembered by some as a &ldquo;financial advisor&rdquo; providing some advice to former teammates.
What Happened: Nassib <a href="https://www.instagram.com/carlnassib/?hl=en">announced</a>&nbsp;he&#39;s gay on his Instagram account: &quot;I&#39;ve been meaning to do this for a while now, but I finally feel comfortable enough to get it off my chest.&quot;
He announced a donation of $100,000 to The Trevor Project, a crisis intervention and suicide prevention organization that works with LGBTQ youth.
Financial Advisor?&nbsp;Nassib was a member of the Cleveland Browns in 2018 when the team was profiled in the series &quot;Hard Knocks.&quot;
&ldquo;Who here knows what compound interest is?&rdquo; Nassib <a href="https://www.youtube.com/watch?v=uN9WSgeETCo">asked </a>his teammates while appearing in front of a dry erase board.
Nassib told his teammates that financial advisors are everywhere and they&rsquo;ll take money from you, but if you learn how to invest yourself, you can make &ldquo;millions of dollars.&rdquo;
&quot;This is the easiest equation to make you rich,&quot; Nassib said.
Nassib&#39;s equation was 1x1.1x1.1x1.1x1.1x1.1x1.1x1.1 showing that an average gain of 10% annually can double your money in seven years. Nassib said&nbsp;doing this same thing for years could turn $1 million into $64 million.
&ldquo;It&#39;s&nbsp;called interest and it&rsquo;s so easy.&rdquo;
Nassib said you could put money in the bank and not touch it to gain interest on it.
<iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" frameborder="0" height="315" src="https://www.youtube.com/embed/uN9WSgeETCo" width="560"></iframe>
Related Link: <a href="https://www.benzinga.com/news/21/06/21646510/sesame-street-adds-two-gay-fathers-to-its-cast-of-characters">Sesame Street Adds Two Gay Fathers To Its Cast Of Characters</a>
10% Returns: The compounded interest principal has been around for years and is a good benchmark for average returns.
&ldquo;The magic of compounding works best the younger you are because that means you have more time for your money to grow,&rdquo; Jim Cramer once <a href="https://www.benzinga.com/media/cnbc/17/07/9740432/how-to-double-your-money-in-7-years-according-to-jim-cramer">said</a>.
The easy benchmark and investment for investors to consider is the S&amp;P 500 or the SPDR S&amp;P 500 ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>), which is a common benchmark of the market.
Investing $10,000 in the ETF for four decades and having 10% of annual returns could equal $450,000 over time.
Cramer said waiting seven years to double an investment may be difficult to understand but is &quot;pretty incredible.&quot;
The SPDR S&amp;P 500 ETF has <a href="https://www.ssga.com/us/en/institutional/etfs/funds/spdr-sp-500-etf-trust-spy">returned </a>14.2% on average annually over the last 10 years. Since the fund&rsquo;s inception, the ETF has posted average yearly gains of 10.4%.
SPY Price Action: The SPDR S&amp;P 500 ETF is up 13.3% in 2021.

Sports

Personal Finance

Carl Nassib — NFL's First Openly Gay Player — Once Provided His Teammates A Lesson On Compound Interest, 10% Annual Returns

Jan Van Eck, the CEO of asset manager Van Eck Associate, urged the United States Securities and Exchange Commission (SEC) to approve a&nbsp;Bitcoin&nbsp;(CRYPTO: BTC) exchange-traded fund due to investor demand.
What Happened:&nbsp;According to a Tuesday CNBC&nbsp;<a href="https://www.cnbc.com/2021/06/22/investors-want-a-bitcoin-etf-van-eck-ceo-says-after-sec-delays-again.html" target="_blank">report</a>, Van Eck said that the regulator &ldquo;should approve a Bitcoin ETF&rdquo; since &ldquo;the only alternative investors have is a closed-end fund that trades it at a 40% premium or 20% discount.&rdquo;&nbsp;
According to CNBC, he was presumably hinting at the&nbsp;Grayscale Bitcoin Trust&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/gbtc#OTC">GBTC</a>), known to be often trading at a premium or discount.
Van Eck&rsquo;s comments follow SEC&rsquo;s decision to yet again delay the regulator&rsquo;s decision to approve the VanEck Bitcoin Trust for the second time, requesting comment from interested parties on how this decision could impact markets.
The asset manager&rsquo;s CEO also mentioned Bitcoin futures, claiming that they &ldquo;aren&#39;t&nbsp;any better,&rdquo; adding a futures-based fund &ldquo;underperformed Bitcoin by 22% last year and 8% this year.&rdquo;
What Else: Ric Edelman, the No. 1 registered investment advisor in the United States and the founder of Edelman Financial Engines, also said that integrating Bitcoin into portfolios would &ldquo;be so much easier and simpler if there was a Bitcoin ETF.&rdquo;
At the same time, he admits that investors have to act instead of waiting because &ldquo;by the time the SEC says yes to it, Bitcoin might be $100,000.&rdquo;&nbsp;
Read also: <a href="https://www.benzinga.com/money/best-crypto-etfs/">What Is Crypto ETFs</a><a href="https://www.benzinga.com/money/best-crypto-etfs/">?</a>
&ldquo;You&rsquo;re going to miss out, so, you&rsquo;ve got to move on with the investment opportunities that do exist,&rdquo; he concluded.

Futures

Management

Van Eck CEO Insists Bitcoin ETF Is A Good Idea After SEC Delays The Decision Once Again

Wallbox is set to go public with a pro-forma enterprise value of $1.5 billion&nbsp;via special purpose acquisition company (SPAC)&nbsp;Kensington Capital Acquisition Corp II (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kcac#NYSE">KCAC</a>).
Enric Asunci&oacute;n, CEO of Wallbox and&nbsp;Justin Mirro, chairman and CEO of Kensington Capital Acquisition Corp II,&nbsp;appeared on&nbsp;<a href="https://www.youtube.com/watch?v=X91_hGkUPUo&amp;t=243s">Benzinga&#39;s YouTube show &quot;SPACs Attack&quot;</a>&nbsp;Tuesday for an exclusive interview.&nbsp;
About Wallbox: Wallbox designs, develops and manufactures intelligent charging systems for electric vehicles,&nbsp;Asunci&oacute;n told Benzinga.
The company is one of the fastest-growing companies in the EV charging space, he said,&nbsp;adding that it focuses on both charging and energy management.
The ability to control its own supply chain gives Wallbox a huge advantage over its competition,&nbsp;Asunci&oacute;n said.&nbsp;Wallbox has 45% gross margins which exceed all of its competition, he added.&nbsp;
The company currently sells its products for home, business&nbsp;and public space use in 67 countries, the Wallbox CEO said.&nbsp;
Company Outlook: The infrastructure in the EV space is a focus among governments and individual investors around the world, Mirro said.&nbsp;
Wallbox makes the simplest, safest and most innovative EV chargers for consumers on the market today, he told Benzinga.&nbsp;
The company has world-leading margins and has already been certified by multiple car manufacturers, Mirro said, adding that it won&#39;t be difficult for Wallbox to meet and even exceed its forecasts.
Wallbox aims to be the provider of all-in-one renewable energy solutions with the charger at the center.
SPAC Notes: Wallbox is growing very quickly and the team&nbsp;at Kensington Capital Acquisitions Corp II shared the same vision for Wallbox, so the SPAC route to the public market was&nbsp;the right fit for the company,&nbsp;Asunci&oacute;n noted.
The team at&nbsp;Kensington Capital Acquisition&nbsp;Corp II has a long history in the automotive space,&nbsp;so Wallbox presented&nbsp;a great merger target opportunity, Mirro added.
The merger is expected to close in the third quarter of 2021.&nbsp;
Pending shareholder approval, the&nbsp;combined company will&nbsp;be listed on the New York Stock Exchange as&nbsp;Wallbox and trade&nbsp;under the&nbsp;ticker symbol &quot;WBX&rdquo;.
Related Link:&nbsp;<a href="https://www.benzinga.com/m-a/21/06/21492325/electric-vehicle-charging-company-wallbox-gets-spac-deal-what-investors-should-know">Electric Vehicle Charging Company Wallbox Gets SPAC Deal: What Investors Should Know</a>
Price Action:&nbsp;Kensington Capital Acquisitions Corp II has traded as high as $25.75 and as low as $9.74 since its IPO in February. At last check Tuesday, the stock was up 0.30% at $9.97.
&nbsp;

Exclusives

Interview

KCAC

EXCLUSIVE: CEOs Of Wallbox And Kensington Capital Acquisition Corp II Talk EV Charging, SPAC Merger On 'SPACs Attack'

<h3>GAINERS:</h3>
<ul>
<li><a href="https://quotes.benzinga.com/quote/HRVOF" target="_blank">Harvest One Cannabis</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/hrvof#OTC">HRVOF</a>) shares closed up 10.96% at $0.08</li>
<li><a href="https://quotes.benzinga.com/quote/CPHRF" target="_blank">Cipher Pharms Inc</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cphrf#OTC">CPHRF</a>) shares closed up 6.35% at $1.34</li>
<li><a href="https://quotes.benzinga.com/quote/HERTF" target="_blank">Heritage Cannabis Holding</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/hertf#OTC">HERTF</a>) shares closed up 5.29% at $0.08</li>
<li><a href="https://quotes.benzinga.com/quote/SEED" target="_blank">Origin Agritech</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seed#NASDAQ">SEED</a>) shares closed up 5.08% at $9.10</li>
<li><a href="https://quotes.benzinga.com/quote/NEPT" target="_blank">Neptune Wellness Solns</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nept#NASDAQ">NEPT</a>) shares closed up 4.17% at $1.25</li>
<li><a href="https://quotes.benzinga.com/quote/SOL" target="_blank">ReneSola</a>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sol#NYSE">SOL</a>) shares closed up 3.7% at $8.12</li>
<li><a href="https://quotes.benzinga.com/quote/GRWG" target="_blank">GrowGeneration</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grwg#NASDAQ">GRWG</a>) shares closed up 2.53% at $42.16</li>
<li><a href="https://quotes.benzinga.com/quote/BLOZF" target="_blank">Cannabix Technologies</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/blozf#OTC">BLOZF</a>) shares closed up 2.34% at $0.87</li>
<li><a href="https://quotes.benzinga.com/quote/MBII" target="_blank">Marrone Bio Innovations</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbii#NASDAQ">MBII</a>) shares closed up 2.29% at $1.79</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://quotes.benzinga.com/quote/MXC" target="_blank">Mexco Energy</a>&nbsp;(AMEX: MXC) shares closed down 8.80% at $8.81</li>
<li><a href="https://quotes.benzinga.com/quote/ELLXF" target="_blank">Elixinol Wellness</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ellxf#OTC">ELLXF</a>) shares closed down 8.46% at $0.11</li>
<li><a href="https://quotes.benzinga.com/quote/PMD" target="_blank">Psychemedics</a>&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmd#NASDAQ">PMD</a>) shares closed down 7.72% at $7.29</li>
<li><a href="https://quotes.benzinga.com/quote/IVITF" target="_blank">Invictus MD Strategies</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ivitf#OTC">IVITF</a>) shares closed down 5.93% at $0.05</li>
<li><a href="https://quotes.benzinga.com/quote/CNGGF" target="_blank">Cann Gr</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnggf#OTC">CNGGF</a>) shares closed down 5.19% at $0.29</li>
<li><a href="https://quotes.benzinga.com/quote/TRSSF" target="_blank">TerrAscend</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/trssf#OTC">TRSSF</a>) shares closed down 4.9% at $9.53</li>
<li><a href="https://quotes.benzinga.com/quote/INLB" target="_blank">Item 9 Labs</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/inlb#OTC">INLB</a>) shares closed down 4.76% at $3.00</li>
<li><a href="https://quotes.benzinga.com/quote/KSHB" target="_blank">KushCo Holdings</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/kshb#OTC">KSHB</a>) shares closed down 4.64% at $0.93</li>
<li><a href="https://quotes.benzinga.com/quote/NXGWF" target="_blank">Next Green Wave Holdings</a>&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/nxgwf#OTC">NXGWF</a>) shares closed down 4.43% at $0.64</li>
<li><a href="https://quotes.benzinga.com/quote/NINE" target="_blank">Nine Energy Service</a>&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nine#NYSE">NINE</a>) shares closed down 4.23% at $2.92</li>
</ul>
<a href="https://www.benzinga.com/cannabis/stocks/">Check out a full list of cannabis stock movers in real-time following this link.</a>
Lead image by Ilona Szentivanyi. Copyright: Benzinga.

Cannabis

After-Hours Center

BLOZF

CNGGF

CPHRF

ELLXF

GRWG

HERTF

HRVOF

INLB

IVITF

KSHB

MBII

NEPT

NINE

NXGWF

SEED

TRSSF

Cannabis Stock Gainers And Losers From June 22, 2021

Design Therapeutics Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $20/Share

Design Therapeutics Shares Open For Trade At $28; IPO Priced At $20/Share

<h3>&nbsp;</h3>

<h3>&nbsp;</h3>

<h3>&nbsp;</h3>

<h3>Gainers</h3>

<ul>
	<li>Elite Education Group International Ltd. (NASDAQ:<a class="ticker" href="/stock/EEIQ#NASDAQ">EEIQ</a>) shares climbed 287.5% to close at $15.50 on Friday. The company, on Thursday, priced its 750,000 unit offering at $8 per unit.</li>
	<li>Wah Fu Education Group Limited (NASDAQ:<a class="ticker" href="/stock/WAFU#NASDAQ">WAFU</a>) shares gained 167.1% to close at $12.66. Chinese education stocks were trading sharply higher Friday morning, potentially following the Thursday IPO of a peer in the space, Elite Education.</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) shares jumped 107.5% to close at $41.49 after the company priced its IPO at $20 per share.</li>
	<li>Ikena Oncology, Inc. (NASDAQ:<a class="ticker" href="/stock/IKNA#NASDAQ">IKNA</a>) surged 100% to close at $32.00 after the company priced its IPO at $16 per share.</li>
	<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/EWTX#NASDAQ">EWTX</a>) gained 87.5% to close at $30.00 after pricing its IPO at $16 per share.</li>
	<li>ThredUp Inc. (NASDAQ:<a class="ticker" href="/stock/TDUP#NASDAQ">TDUP</a>) rose 42.9% to close at $20.00 as the company priced its IPO at $14 a share.</li>
	<li>Big Rock Partners Acquisition Corp. (NASDAQ:<a class="ticker" href="/stock/BRPA#NASDAQ">BRPA</a>) gained 36.4% to close at $35.89 after the company announced the completion of top line data analysis in its Phase 2b/3 clinical trial of ZYESAMI for the treatment of COVID-19 respiration failure.</li>
	<li>Four Seasons Education (Cayman) Inc. (NYSE:<a class="ticker" href="/stock/FEDU#NYSE">FEDU</a>) climbed 34.3% to close at $1.80. Chinese education stocks were trading sharply higher Friday morning, potentially following the Thursday IPO of a peer in the space, Elite Education.</li>
	<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="/stock/NEXT#NASDAQ">NEXT</a>) climbed 31.8% to close at $2.57 after the company, and Oxy Low Carbon Ventures, signed a term sheet for CO2 transportation and storage in South Texas.</li>
	<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="/stock/HSDT#NASDAQ">HSDT</a>) gained 30.8% to close at $18.12 after it was reported the FDA authorized marketing authorization of the Portable Neuromodulation Stimulator to Helius Medical.</li>
	<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="/stock/CLEU#NASDAQ">CLEU</a>) rose 29% to close at $4.94. Chinese education stocks were trading sharply higher Friday morning, potentially following the Thursday IPO of a peer in the space, Elite Education.</li>
	<li>Tuya Inc. (NYSE:<a class="ticker" href="/stock/TUYA#NYSE">TUYA</a>) rose 28.7% to close at $24.64.</li>
	<li>MagnaChip Semiconductor Corporation (NYSE:<a class="ticker" href="/stock/MX#NYSE">MX</a>) gained 27.4% to close at $26.01 after the company reported a deal whereby Wise Road Capital will take the company private at $29 per share in cash.</li>
	<li>ATA Creativity Global (NASDAQ:<a class="ticker" href="/stock/AACG#NASDAQ">AACG</a>) rose 23.9% to close at $4.92.</li>
	<li>Telos Corporation (NASDAQ:<a class="ticker" href="/stock/TLS#NASDAQ">TLS</a>) rose 22.6% to close at $37.71 after the company reported better-than-expected Q4 results and issued strong sales guidance.</li>
	<li>Duos Technologies Group, Inc. (NASDAQ:<a class="ticker" href="/stock/DUOT#NASDAQ">DUOT</a>) gained 21.1% to close at $10.45 following Q4 results.</li>
	<li>XOMA Corporation (NASDAQ:<a class="ticker" href="/stock/XOMA#NASDAQ">XOMA</a>) jumped 20.4% to close at $39.99.</li>
	<li>BowX Acquisition Corp. (NASDAQ:<a class="ticker" href="/stock/BOWX#NASDAQ">BOWX</a>) gained 20.4% to close at $11.71 after the company, and WeWork, announced they entered into a definitive merger agreement, providing for a business combination that will result in WeWork becoming a publicly listed company..</li>
	<li>Banco Santadr Mc SA In de Bn Ml Gp (NYSE:<a class="ticker" href="/stock/BSMX#NYSE">BSMX</a>) rose 19.4% to close at $5.60.</li>
	<li>Mechanical Technology, Incorporated (NASDAQ:<a class="ticker" href="/stock/MKTY#NASDAQ">MKTY</a>) gained 19.4% to close at $13.25.</li>
	<li>Mexco Energy Corporation (NYSE:<a class="ticker" href="/stock/MXC#NYSE">MXC</a>) surged 18.9% to close at $9.23.</li>
	<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="/stock/ATNF#NASDAQ">ATNF</a>) shares rose 18.6% to close at $6.96. 180 Life Sciences reported availability of broadcast &#39;controlling inflammation to stop disease.&#39;</li>
	<li>Century Aluminum Company (NASDAQ:<a class="ticker" href="/stock/CENX#NASDAQ">CENX</a>) climbed 17.4% to close at $18.53.</li>
	<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/UPST#NASDAQ">UPST</a>) jumped 15.5% to close at $142.95.</li>
	<li>Nordic American Tankers Limited (NYSE:<a class="ticker" href="/stock/NAT#NYSE">NAT</a>) gained 14.8% to close at $3.88 after a company board member purchased 50,000 shares at $3.69 per share. Strength in tankers may also be related to the Suez canal blockage.</li>
	<li>FreightCar America, Inc. (NASDAQ:<a class="ticker" href="/stock/RAIL#NASDAQ">RAIL</a>) rose 14.4% to close at $5.49. The company recently reported upbeat quarterly sales.</li>
	<li>Ubiquiti Inc. (NYSE:<a class="ticker" href="/stock/UI#NYSE">UI</a>) climbed 14.2% to close at $389.88.</li>
	<li>Future FinTech Group Inc.. (NASDAQ:<a class="ticker" href="/stock/FTFT#NASDAQ">FTFT</a>) gained 13.7% to close at $5.90. Future FinTech recently announced plans to acquire 60% of Guang Dong Hi-Card Business Service Co., Ltd. for $9.2 million.</li>
	<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SLRX#NASDAQ">SLRX</a>) rose 13% to close at $1.56. Salarius Pharmaceuticals, last week, reported Q4 results.</li>
	<li>Palatin Technologies, Inc. (NYSE:<a class="ticker" href="/stock/PTN#NYSE">PTN</a>) rose 12.7% to close at $0.7830.</li>
	<li>United States Steel Corporation (NYSE:<a class="ticker" href="/stock/X#NYSE">X</a>) gained 11.7% to close at $22.75 potentially amid US infrastructure optimism and outlook for an economic recovery, both of which could lift demand.</li>
	<li>Root, Inc. (NASDAQ:<a class="ticker" href="/stock/ROOT#NASDAQ">ROOT</a>) rose 11.4% to close at $14.34.</li>
	<li>SEACOR Marine Holdings Inc. (NYSE:<a class="ticker" href="/stock/SMHI#NYSE">SMHI</a>) gained 9.5% to close at $5.79. The company recently released Q4 results.</li>
	<li>Vizio Holding Corp. (NASDAQ:<a class="ticker" href="/stock/VZIO#NASDAQ">VZIO</a>) gained 8.6% to close at $20.75. Vizio recently priced its IPO at $21 per share.</li>
	<li>Jianpu Technology Inc. (NYSE:<a class="ticker" href="/stock/JT#NYSE">JT</a>) gained 7.7% to close at $2.67.</li>
	<li>LAIX Inc. (NYSE:<a class="ticker" href="/stock/LAIX#NYSE">LAIX</a>) shares gained 6.3% to close at $2.52. Chinese education stocks were trading sharply higher Friday morning, potentially following the Thursday IPO of a peer in the space, Elite Education.</li>
</ul>

&nbsp;

&nbsp;

<h3>Losers</h3>

<ul>
	<li>GSX Techedu Inc. (NYSE:<a class="ticker" href="/stock/GSX#NYSE">GSX</a>) dipped 49.6% to close at $39.01. Shares of large-cap Chinese education stocks traded lower amid potential investor rotation into smaller-cap names in the sector.</li>
	<li>Discovery, Inc. (NASDAQ:<a class="ticker" href="/stock/DISCK#NASDAQ">DISCK</a>) shares tumbled 29.6% to close at $35.96 on Friday.</li>
	<li>ViacomCBS Inc. (NASDAQ:<a class="ticker" href="/stock/VIAC#NASDAQ">VIAC</a>) dropped 27.3% to close at $48.23.</li>
	<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="/stock/DLPN#NASDAQ">DLPN</a>) fell 25.7% to close at $13.25. Hall of Fame Resort &amp; Entertainment recently announced it signed a Non-Fungible Token partnership with Dolphin Entertainment.</li>
	<li>Rubius Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/RUBY#NASDAQ">RUBY</a>) dropped 22.5% to close at $24.62.</li>
	<li>Co-Diagnostics Inc (NASDAQ:<a class="ticker" href="/stock/CODX#NASDAQ">CODX</a>) dropped 20% to close at $9.70 after the company reported downbeat earnings for its fourth quarter.</li>
	<li>HighPoint Resources Corporation (NYSE:<a class="ticker" href="/stock/HPR#NYSE">HPR</a>) shares fell 20% to close at $6.20 after dropping over 28% on Thursday.</li>
	<li>Antelope Enterprise Holdings Limited (NASDAQ:<a class="ticker" href="/stock/AEHL#NASDAQ">AEHL</a>) dropped 19.5% to close at $3.14.</li>
	<li>Cloopen Group Holding Limited (NASDAQ:<a class="ticker" href="/stock/RAAS#NASDAQ">RAAS</a>) fell 18.5% to close at $11.75 following Q4 results.</li>
	<li>Koss Corporation (NASDAQ:<a class="ticker" href="/stock/KOSS#NASDAQ">KOSS</a>) dipped 18.1% to close at $21.13. Koss shares climbed 57% on Thursday amid continued interest in the stock from retail investors.</li>
	<li>Science Applications International Corporation (NYSE:<a class="ticker" href="/stock/SAIC#NYSE">SAIC</a>) fell 16.6% to close at $80.00 after the company reported worse-than-expected Q4 sales and issued weak FY22 EPS and sales guidance.</li>
	<li>Elevate Credit, Inc. (NYSE:<a class="ticker" href="/stock/ELVT#NYSE">ELVT</a>) shares fell 16.2% to close at $3.10. Elevate Credit, last month, reported better-than-expected Q4 EPS results.</li>
	<li>Liquid Media Group Ltd. (NASDAQ:<a class="ticker" href="/stock/YVR#NASDAQ">YVR</a>) dipped 16.1% to close at $3.70.</li>
	<li>Cellect Biotechnology Ltd. (NASDAQ:<a class="ticker" href="/stock/APOP#NASDAQ">APOP</a>) fell 15.7% to close at $4.02. Cellect Biotechnology shares climbed over 36% on Thursday after the company and Quoin Pharmaceuticals announced a strategic merger.</li>
	<li>GigaMedia Limited (NASDAQ:<a class="ticker" href="/stock/GIGM#NASDAQ">GIGM</a>) dipped 15.5% to close at $3.81.</li>
	<li>Immutep Limited (NASDAQ:<a class="ticker" href="/stock/IMMP#NASDAQ">IMMP</a>) dropped 15.5% to close at $3.11 potentially on profit-taking after the stock rallied roughly 40% yesterday.</li>
	<li>fuboTV Inc. (NASDAQ:<a class="ticker" href="/stock/FUBO#NASDAQ">FUBO</a>) fell 15.5% to close at $21.88.</li>
	<li>Odonate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/ODT#NASDAQ">ODT</a>) shares declined 14.4% to close at $3.09.</li>
	<li>Youdao, Inc. (NYSE:<a class="ticker" href="/stock/DAO#NYSE">DAO</a>) dropped 13.7% to close at $24.96.</li>
	<li>Gan Ltd (NASDAQ:<a class="ticker" href="/stock/GAN#NASDAQ">GAN</a>) fell 13.5% to close at $19.98. Gan reported weaker-than-expected results for its fourth quarter, but issued strong sales forecast.</li>
	<li>Vuzix Corporation (NASDAQ:<a class="ticker" href="/stock/VUZI#NASDAQ">VUZI</a>) fell 13.2% to close at $22.84 after the company priced 4.1 million shares at $20.5 per share in a secondary public offering to raise $85 million in gross proceeds.</li>
	<li>Cinedigm Corp. (NASDAQ:<a class="ticker" href="/stock/CIDM#NASDAQ">CIDM</a>) fell 12% to close at $1.69. Cinedigm shares jumped over 18% on Thursday after the company announced on Twitter its product team will develop &quot;new #NFT products to enhance the user experience of our loyal audiences.&quot;</li>
	<li>New Oriental Education &amp; Technology Group Inc. (NYSE:<a class="ticker" href="/stock/EDU#NYSE">EDU</a>) fell 11.1% to close at $14.23. Shares of large-cap Chinese education stocks traded lower amid potential investor rotation into smaller-cap names in the sector.</li>
	<li>SenesTech, Inc. (NASDAQ:<a class="ticker" href="/stock/SNES#NASDAQ">SNES</a>) fell 9.6% to close at $1.78 after the company reported FY20 results.</li>
	<li>Hall of Fame Resort &amp; Entertainment Company (NASDAQ:<a class="ticker" href="/stock/HOFV#NASDAQ">HOFV</a>) fell 9.2% to close at $5.15. Hall Of Fame Resort &amp; Entertainment recently announced a Non-Fungible Token partnership with Dolphin Entertainment.</li>
	<li>JOYY Inc. (NASDAQ:<a class="ticker" href="/stock/YY#NASDAQ">YY</a>) fell 8.4% to close at $96.13 following Q4 results.</li>
	<li>TAL Education Group (NYSE:<a class="ticker" href="/stock/TAL#NYSE">TAL</a>) fell 7.4% to close at $56.20. Shares of large-cap Chinese education stocks traded lower amid potential investor rotation into smaller-cap names in the sector.</li>
</ul>

63 Biggest Movers From Friday

<h3>Gainers</h3>

&nbsp;

<ul>
	<li>ThredUp Inc. (NASDAQ:<a class="ticker" href="/stock/TDUP#NASDAQ">TDUP</a>) shares jumped 57% to close at $31.40 on Monday. The company, on Friday, priced its IPO at $14 a share.</li>
	<li>Humanigen, Inc. (NASDAQ:<a class="ticker" href="/stock/HGEN#NASDAQ">HGEN</a>) shares surged 54.5% to close at $21.61 on Monday after the company reported topline data from Phase 3 study evaluating its lead drug candidate, lenzilumab, in patients hospitalized with COVID-19.</li>
	<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="/stock/UPC#NASDAQ">UPC</a>) gained 37.8% to close at $5.61. Universe Pharmaceuticals, last week, priced its IPO at $5 per share.</li>
	<li>China Pharma Holdings, Inc. (NYSE:<a class="ticker" href="/stock/CPHI#NYSE">CPHI</a>) shares climbed 37% to close at $1.14 after the company reported a narrower FY20 loss late Friday.</li>
	<li>Hall of Fame Resort &amp; Entertainment Company (NASDAQ:<a class="ticker" href="/stock/HOFV#NASDAQ">HOFV</a>) climbed 31.1% to close at $6.75. Hall of Fame Resort &amp; Entertainment recently announced it signed a Non-Fungible Token partnership with Dolphin Entertainment.</li>
	<li>Cyanotech Corporation (NASDAQ:<a class="ticker" href="/stock/CYAN#NASDAQ">CYAN</a>) jumped 30.6% to close at $4.14.</li>
	<li>Fly Leasing Limited (NYSE:<a class="ticker" href="/stock/FLY#NYSE">FLY</a>) gained 27.5% to close at $16.89 after Carlyle Aviation said it would acquire the company for $17.05 per share.</li>
	<li>Trinity Biotech plc (NASDAQ:<a class="ticker" href="/stock/TRIB#NASDAQ">TRIB</a>) jumped 24.8% to close at $4.07.</li>
	<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/EWTX#NASDAQ">EWTX</a>) gained 20% to close at $35.99. The company, on Friday, priced its IPO at $16 per share.</li>
	<li>Elite Education Group International Limited (NASDAQ:<a class="ticker" href="/stock/EEIQ#NASDAQ">EEIQ</a>) gained 19.6% to close at $18.54 after climbing more than 287% on Friday. The company, on Thursday, priced its 750,000 unit offering at $8 per unit.</li>
	<li>Recon Technology, Ltd. (NASDAQ:<a class="ticker" href="/stock/RCON#NASDAQ">RCON</a>) gained 19% to close at $8.59.</li>
	<li>EDAP TMS S.A. (NYSE:<a class="ticker" href="/stock/EDAP#NYSE">EDAP</a>) climbed 18.8% to close at $9.68.</li>
	<li>Houghton Mifflin Harcourt Company (NASDAQ:<a class="ticker" href="/stock/HMHC#NASDAQ">HMHC</a>) rose 18.7% to close at $7.10. Houghton Mifflin Harcourt inked an agreement to divest its consumer publishing business, HMH Books &amp; Media, to News Corp division HarperCollins Publishers for $349 million cash.</li>
	<li>Mer Telemanagement Solutions Ltd. (NASDAQ:<a class="ticker" href="/stock/MTSL#NASDAQ">MTSL</a>) gained 18.2% to close at $3.50.</li>
	<li>RLX Technology Inc. (NYSE:<a class="ticker" href="/stock/RLX#NYSE">RLX</a>) surged 17% to close at $10.67.</li>
	<li>Sphere 3D Corp. (NASDAQ:<a class="ticker" href="/stock/ANY#NASDAQ">ANY</a>) jumped 16.7% to close at $2.44. Sphere 3D, last week, filed for common stock offering.</li>
	<li>Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="/stock/KZIA#NASDAQ">KZIA</a>) gained 15.7% to close at $12.86 as the company said it has Licensed the rights to paxalisib in Greater China to Simcere Pharmaceutical Group.</li>
	<li>Futu Holdings Limited (NASDAQ:<a class="ticker" href="/stock/FUTU#NASDAQ">FUTU</a>) jumped 14.7% to close at $131.51.</li>
	<li>Big Rock Partners Acquisition Corp. (NASDAQ:<a class="ticker" href="/stock/BRPA#NASDAQ">BRPA</a>) gained 14.6% to close at $41.12 after its merging partner NeuroRx announced ZYESAMI met the primary endpoint of its Phase 2b/3 clinical trial and also demonstrated a meaningful benefit in survival from critical COVID-19.</li>
	<li>Dolphin Entertainment, Inc. (NASDAQ:<a class="ticker" href="/stock/DLPN#NASDAQ">DLPN</a>) gained 7.9% to close at $14.30. Hall of Fame Resort &amp; Entertainment recently announced it signed a Non-Fungible Token partnership with Dolphin Entertainment.</li>
	<li>China SXT Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SXTC#NASDAQ">SXTC</a>) rose 7.7% to close at $1.97.</li>
	<li>WISeKey International Holding AG (NASDAQ:<a class="ticker" href="/stock/WKEY#NASDAQ">WKEY</a>) rose 7.5% to close at $16.38. WISeKey and Jean-Claude Biver announced first NFT auction of a luxury watch.</li>
</ul>

&nbsp;

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>) fell 36.7% to close at $1.38. Millendo Therapeutics agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction.</li>
	<li>Summer Infant, Inc. (NASDAQ:<a class="ticker" href="/stock/SUMR#NASDAQ">SUMR</a>) dipped 32.1% to close at $14.78.</li>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="/stock/ORPH#NASDAQ">ORPH</a>) shares tumbled 29% to close at $8.80 on Monday after the company&#39;s Phase 2/3 trial evaluating armioclomol for treatment of inclusion body myositis did not meet its primary and secondary endpoints.</li>
	<li>F-star Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FSTX#NASDAQ">FSTX</a>) declined 28.3% to close at $9.22 after the company reported FY20 results.</li>
	<li>Takung Art Co., Ltd. (NASDAQ:<a class="ticker" href="/stock/TKAT#NASDAQ">TKAT</a>) dropped 22.8% to close at $30.50.</li>
	<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="/stock/CLEU#NASDAQ">CLEU</a>) dropped 21.9% to close at $3.86 after climbing 29% on Friday.</li>
	<li>Wah Fu Education Group Limited (NASDAQ:<a class="ticker" href="/stock/WAFU#NASDAQ">WAFU</a>) dropped 21.6% to close at $9.92 after jumping 167% on Friday.</li>
	<li>ToughBuilt Industries, Inc. (NASDAQ:<a class="ticker" href="/stock/TBLT#NASDAQ">TBLT</a>) fell 21.6% to close at $0.9016 after the company reported financial results for the fiscal year ended December 31, 2020.</li>
	<li>HighPoint Resources Corporation (NYSE:<a class="ticker" href="/stock/HPR#NYSE">HPR</a>) fell 21% to close at $4.90 after dipping 20% on Friday.</li>
	<li>LiveXLive Media, Inc.(NASDAQ:<a class="ticker" href="/stock/LIVX#NASDAQ">LIVX</a>) fell 20.5% to close at $4.43. LiveXLive Media, on Friday, said it will launch Non-Fungible Tokens content division based on its global IP and deep roster of talent and mega events.</li>
	<li>Four Seasons Education (Cayman) Inc. (NYSE:<a class="ticker" href="/stock/FEDU#NYSE">FEDU</a>) fell 19.4% to close at $1.45 after climbing over 34% on Friday.</li>
	<li>GSX Techedu Inc. (NYSE:<a class="ticker" href="/stock/GSX#NYSE">GSX</a>) dipped 18.5% to close at $31.78. Citigroup upgraded GSX Techedu from Sell to Buy and lowered the price target from $66 to $56.</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) dropped 18% to close at $34.01. The company, on Friday, priced its IPO at $20 per share.</li>
	<li>Tuya Inc. (NYSE:<a class="ticker" href="/stock/TUYA#NYSE">TUYA</a>) fell 17.8% to close at $20.25. Tuya, earlier during the month, priced its IPO at $20 a share.</li>
	<li>Benitec Biopharma Inc. (NASDAQ:<a class="ticker" href="/stock/BNTC#NASDAQ">BNTC</a>) shares declined 17.7% to close at $4.29.</li>
	<li>Mannatech, Incorporated (NASDAQ:<a class="ticker" href="/stock/MTEX#NASDAQ">MTEX</a>) dipped 17.4% to close at $14.46.</li>
	<li>Cellect Biotechnology Ltd. (NASDAQ:<a class="ticker" href="/stock/APOP#NASDAQ">APOP</a>) fell 16.2% to close at $3.37. Cellect Biotechnology and Quoin Pharmaceuticals, last week, announced a strategic merger.</li>
	<li>Annovis Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/ANVS#NASDAQ">ANVS</a>) dropped 15.7% to close at $25.92.</li>
	<li>Calix, Inc. (NYSE:<a class="ticker" href="/stock/CALX#NYSE">CALX</a>) fell 15.6% to close at $32.48 after BWS Financial initiated coverage on the stock with a Sell rating and announced a price target of $13 per share.</li>
	<li>KBS Fashion Group Limited (NASDAQ:<a class="ticker" href="/stock/KBSF#NASDAQ">KBSF</a>) fell 15.2% to close at $3.69. KBS Fashion Group, the operator of Luxventure, said it closed cross-border payment with Hainan New Generation Technology.</li>
	<li>Arrival (NASDAQ:<a class="ticker" href="/stock/ARVL#NASDAQ">ARVL</a>) dropped 14.1% to close at $19.11.</li>
	<li>Nomura Holdings, Inc. (NYSE:<a class="ticker" href="/stock/NMR#NYSE">NMR</a>) fell 14.1% to close at $5.68 after the bank said it face the potential loss of billions of dollars due to a hedge fund&#39;s default on margin calls late last week.</li>
	<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/CLDX#NASDAQ">CLDX</a>) fell 13.8% to close at $20.47 after the company reported interim data from the ongoing Phase 1b trial, evaluating CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU) and symptomatic dermographism (SD), the two most common forms of chronic inducible urticaria (CIndU).</li>
	<li>Fossil Group, Inc. (NASDAQ:<a class="ticker" href="/stock/FOSL#NASDAQ">FOSL</a>) dipped 13.3% to close at $11.99.</li>
	<li>iHuman Inc. (NYSE:<a class="ticker" href="/stock/IH#NYSE">IH</a>) shares declined 13.2% to close at $11.11. The company, last week, released Q4 results.</li>
	<li>Ikena Oncology, Inc. (NASDAQ:<a class="ticker" href="/stock/IKNA#NASDAQ">IKNA</a>) fell 11.6% to close at $28.30. Ikena Oncology surged 100% on Friday after the company priced its IPO at $16 per share.</li>
	<li>Credit Suisse Group AG (NYSE:<a class="ticker" href="/stock/CS#NYSE">CS</a>) fell 11.5% to close at $11.39 after the bank said it face the potential loss of billions of dollars due to a hedge fund&#39;s default on margin calls late last week.</li>
	<li>ATA Creativity Global (NASDAQ:<a class="ticker" href="/stock/AACG#NASDAQ">AACG</a>) fell 11.4% to close at $4.36 after climbing 24% on Friday.</li>
</ul>

50 Biggest Movers From Yesterday

<h3>Gainers</h3>

&nbsp;

<ul>
	<li>VirTra, Inc. (NASDAQ:<a class="ticker" href="/stock/VTSI#NASDAQ">VTSI</a>) shares surged 66.7% to close at $7.97 on Tuesday after the company reported better-than-expected Q4 results.</li>
	<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="/stock/CSCW#NASDAQ">CSCW</a>) climbed 35.8% to close at $1.82 after the company announced the development and application of its non-fungible token for its entertainment business.</li>
	<li>Mannatech, Incorporated (NASDAQ:<a class="ticker" href="/stock/MTEX#NASDAQ">MTEX</a>) rose 31.4% to close at $19.00. Mannatech, earlier during the month, reported Q4 results.</li>
	<li>VivoPower International PLC (NASDAQ:<a class="ticker" href="/stock/VVPR#NASDAQ">VVPR</a>) gained 31.4% to close at $10.59.</li>
	<li>Moxian, Inc. (NASDAQ:<a class="ticker" href="/stock/MOXC#NASDAQ">MOXC</a>) surged 29.3% to close at $3.88.</li>
	<li>Discovery, Inc. (NASDAQ:<a class="ticker" href="/stock/DISCB#NASDAQ">DISCB</a>) shares rose 28.9% to close at $70.01.</li>
	<li>HighPoint Resources Corporation (NYSE:<a class="ticker" href="/stock/HPR#NYSE">HPR</a>) surged 24.5% to close at $6.10.</li>
	<li>CompX International Inc. (NYSE:<a class="ticker" href="/stock/CIX#NYSE">CIX</a>) rose 23.7% to close at $18.82.</li>
	<li>Performant Financial Corporation (NASDAQ:<a class="ticker" href="/stock/PFMT#NASDAQ">PFMT</a>) shares gained 22.8% to close at $1.83 after the company reported Q4 results and announced strategic initiatives to focus on healthcare.</li>
	<li>Lizhi Inc. (NASDAQ:<a class="ticker" href="/stock/LIZI#NASDAQ">LIZI</a>) surged 22.4% to close at $8.64. LIZHI recently announced in-car audio collaboration with new energy vehicle company ENOVATE Motors.</li>
	<li>Broadwind, Inc. (NASDAQ:<a class="ticker" href="/stock/BWEN#NASDAQ">BWEN</a>) gained 22.4% to close at $6.13.</li>
	<li>ReneSola Ltd (NYSE:<a class="ticker" href="/stock/SOL#NYSE">SOL</a>) rose 20.8% to close at $11.84. The company, last week, reported Q4 results.</li>
	<li>Canaan Inc. (NASDAQ:<a class="ticker" href="/stock/CAN#NASDAQ">CAN</a>) shares surged 20.7% to close at $21.26.</li>
	<li>GreenPower Motor Company Inc. (NASDAQ:<a class="ticker" href="/stock/GP#NASDAQ">GP</a>) gained 19.4% to close at $21.85.</li>
	<li>ShockWave Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/SWAV#NASDAQ">SWAV</a>) climbed 19.3% to close at $122.89. Shockwave Medical recently announced a joint venture in China.</li>
	<li>Spark Networks SE (NYSE:<a class="ticker" href="/stock/LOV#NYSE">LOV</a>) gained 18.7% to close at $7.42.</li>
	<li>Cloopen Group Holding Limited (NYSE:<a class="ticker" href="/stock/RAAS#NYSE">RAAS</a>) surged 18.5% to close at $13.76. Cloopen Group, last week, released Q4 results.</li>
	<li>Cyclo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/CYTH#NASDAQ">CYTH</a>) gained 18.1% to close at $8.37. Cyclo Therapeutics recently announced the Phase 1/2 trial of Trappsol Cyclo in rare disease Niemann-Pick Type C1 met its primary endpoint.</li>
	<li>PAVmed Inc. (NASDAQ:<a class="ticker" href="/stock/PAVM#NASDAQ">PAVM</a>) surged 17.8% to close at $4.63 after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and a price target of $8 per share.</li>
	<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="/stock/NINE#NYSE">NINE</a>) gained 17.3% to close at $2.44.</li>
	<li>Novan, Inc. (NASDAQ:<a class="ticker" href="/stock/NOVN#NASDAQ">NOVN</a>) rose 16.8% to close at $1.60 after dropping over 4% on Monday.</li>
	<li>Gulf Island Fabrication, Inc. (NASDAQ:<a class="ticker" href="/stock/GIFI#NASDAQ">GIFI</a>) gained 16.6% to close at $4.14 following Q4 results.</li>
	<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="/stock/INVO#NASDAQ">INVO</a>) rose 16.5% to close at $4.94. INVO Biosciences reported FY20 sales of $1.038 million.</li>
	<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SEEL#NASDAQ">SEEL</a>) jumped 16.4% to close at $4.96 after B. Riley FBR initiated coverage on the stock with a Buy rating and a price target of $15 per share.</li>
	<li>Monopar Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/MNPR#NASDAQ">MNPR</a>) rose 16.3% to close at $6.70 as the company announced the publication of a peer-reviewed study that demonstrated Monopar&#39;s Urokinase plasminogen activator (uPA) antibody fragment radiotracer could potentially identify breast cancers with uPA overexpression and monitor uPA activity during treatment using PET imaging.</li>
	<li>Silvergate Capital Corporation (NYSE:<a class="ticker" href="/stock/SI#NYSE">SI</a>) rose 15.4% to close at $139.51 after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $90 to $150.</li>
	<li>NL Industries, Inc. (NYSE:<a class="ticker" href="/stock/NL#NYSE">NL</a>) gained 15.4% to close at $7.72.</li>
	<li>Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="/stock/MBRX#NASDAQ">MBRX</a>) surged 14.9% to close at $4.25. The FDA has approved Moleculin Biotech&rsquo;s request for Fast Track Designation for its drug, Annamycin, to treat soft tissue sarcoma (STS) lung metastases.</li>
	<li>J.Jill, Inc. (NYSE:<a class="ticker" href="/stock/JILL#NYSE">JILL</a>) gained 14.7% to close at $9.68.</li>
	<li>AbCellera Biologics Inc. (NASDAQ:<a class="ticker" href="/stock/ABCL#NASDAQ">ABCL</a>) rose 14.6% to close at $26.68 after the company swung to a profit in FY20.</li>
	<li>The9 Limited (NASDAQ:<a class="ticker" href="/stock/NCTY#NASDAQ">NCTY</a>) rose 14.1% to close at $41.40 after the company reported 2020 results.</li>
	<li>Daqo New Energy Corp. (NYSE:<a class="ticker" href="/stock/DQ#NYSE">DQ</a>) rose 13.6% to close at $70.58.</li>
	<li>Jiayin Group Inc. (NASDAQ:<a class="ticker" href="/stock/JFIN#NASDAQ">JFIN</a>) shares gained 12.3% to close at $8.70.</li>
	<li>Takung Art Co., Ltd. (NASDAQ:<a class="ticker" href="/stock/TKAT#NASDAQ">TKAT</a>) surged 11.8% to close at $34.10 after dropping over 22% on Monday.</li>
	<li>Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="/stock/ASO#NASDAQ">ASO</a>) gained 10.8% to close at $26.88 after the company reported better-than-expected Q4 results.</li>
	<li>REV Group, Inc. (NYSE:<a class="ticker" href="/stock/REVG#NYSE">REVG</a>) rose 10.1% to close at $19.50.</li>
	<li>Vipshop Holdings Limited (NYSE:<a class="ticker" href="/stock/VIPS#NYSE">VIPS</a>) climbed 8.6% to close at $30.93 after the company announced a $500 million buyback.</li>
	<li>Orphazyme A/S (NASDAQ:<a class="ticker" href="/stock/ORPH#NASDAQ">ORPH</a>) rose 5.5% to close at $9.28. Orphazyme shares tumbled 29% on Monday after the company&#39;s Phase 2/3 trial evaluating armioclomol for treatment of inclusion body myositis did not meet its primary and secondary endpoints.</li>
</ul>

&nbsp;

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>AeroCentury Corp. (NYSE:<a class="ticker" href="/stock/ACY#NYSE">ACY</a>) shares dipped 46.5% to close at $3.70 after the company reported that it filed a petition for a Chapter 11 reorganization.</li>
	<li>Elite Education Group International Limited (NASDAQ:<a class="ticker" href="/stock/EEIQ#NASDAQ">EEIQ</a>) shares tumbled 35.5% to close at $11.95 on Tuesday after jumping around 20% on Monday. The company, last week, priced its 750,000 unit offering at $8 per unit.</li>
	<li>ThredUp Inc. (NASDAQ:<a class="ticker" href="/stock/TDUP#NASDAQ">TDUP</a>) dropped 29.8% to close at $22.05. ThredUp, last week, priced its IPO at $14 a share.</li>
	<li>Recon Technology, Ltd. (NASDAQ:<a class="ticker" href="/stock/RCON#NASDAQ">RCON</a>) dipped 29.5% to close at $6.06.</li>
	<li>SeaChange International, Inc. (NASDAQ:<a class="ticker" href="/stock/SEAC#NASDAQ">SEAC</a>) fell 29.3% to close at $1.47 after the company priced its 10,323,484 share common stock offering at $1.85 per share.</li>
	<li>Trxade Group, Inc. (NASDAQ:<a class="ticker" href="/stock/MEDS#NASDAQ">MEDS</a>) fell 27.1% to close at $5.21. Trxade Group posted a net loss of $0.29 per share in the fourth quarter versus a year-ago net loss of $0.04 per shares. Its revenue climbed 17.1% to $2 million.</li>
	<li>Vinco Ventures, Inc. (NASDAQ:<a class="ticker" href="/stock/BBIG#NASDAQ">BBIG</a>) fell 25.7% to close at $2.55.</li>
	<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="/stock/UPC#NASDAQ">UPC</a>) dipped 22.1% to close at $4.37 after jumping over 37% on Monday. Universe Pharmaceuticals, last week, priced its IPO at $5 per share.</li>
	<li>Canoo Inc. (NASDAQ:<a class="ticker" href="/stock/GOEV#NASDAQ">GOEV</a>) dipped 21.2% to close at $9.30 following Q4 earnings. Roth Capital downgraded Canoo from Buy to Neutral and lowered the price target from $30 to $12.</li>
	<li>Genius Brands International, Inc. (NASDAQ:<a class="ticker" href="/stock/GNUS#NASDAQ">GNUS</a>) fell 20.2% to close at $2.07. Genius Brands International announced Stan Lee content collaboration with Marvel Studios.</li>
	<li>Glory Star New Media Group Holdings Limited (NASDAQ:<a class="ticker" href="/stock/GSMG#NASDAQ">GSMG</a>) fell 19.6% to close at $3.74 after reporting FY20 results.</li>
	<li>Hall of Fame Resort &amp; Entertainment Company (NASDAQ:<a class="ticker" href="/stock/HOFV#NASDAQ">HOFV</a>) dropped 18.5% to close at $5.50 after the company announced cities, teams and logos for its Hall of Fantasy league.</li>
	<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="/stock/PCVX#NASDAQ">PCVX</a>) fell 17.9% to close at $18.66 after the company reported Q4 earnings results.</li>
	<li>China Pharma Holdings, Inc. (NYSE:<a class="ticker" href="/stock/CPHI#NYSE">CPHI</a>) fell 17.2% to close at $0.9438. China Pharma shares jumped 37% on Monday after the company reported FY20 earnings results.</li>
	<li>Wah Fu Education Group Limited (NASDAQ:<a class="ticker" href="/stock/WAFU#NASDAQ">WAFU</a>) fell 16.6% to close at $8.27 after dropping around 22% on Monday.</li>
	<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="/stock/WVE#NASDAQ">WVE</a>) shares dipped 15.9% to close at $5.96 on Tuesday after the company announced data from the Phase 1b/2a trials evaluating investigational treatments WVE-120102 and WVE-120101, in Huntington&#39;s disease, showing both candidates did not produce statistically significant change in mutant huntingtin protein versus placebo after single or multiple doses. The company said it will stop the study of both candidates and instead focus on WVE-120103.</li>
	<li>LifeMD, Inc. (NASDAQ:<a class="ticker" href="/stock/LFMD#NASDAQ">LFMD</a>) shares dropped 15.3% to close at $15.98 after the company reported worse-than-expected Q4 results.</li>
	<li>Cyanotech Corporation (NASDAQ:<a class="ticker" href="/stock/CYAN#NASDAQ">CYAN</a>) fell 15.2% to close at $3.51 after jumping more than 30% on Monday.</li>
	<li>Applied Molecular Transport Inc. (NASDAQ:<a class="ticker" href="/stock/AMTI#NASDAQ">AMTI</a>) fell 14% to close at $42.01 after reporting a 2.5 million share offering of common stock.</li>
	<li>Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/EWTX#NASDAQ">EWTX</a>) fell 13.3% to close at $31.22. The company, last week, priced its IPO at $16 per share.</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) dipped 13.2% to close at $29.52. The company, last week, priced its IPO at $20 per share.</li>
	<li>Mechanical Technology, Incorporated (NASDAQ:<a class="ticker" href="/stock/MKTY#NASDAQ">MKTY</a>) fell 12.9% to close at $11.33.</li>
	<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/SONN#NASDAQ">SONN</a>) dropped 12.1% to close at $2.0750 after the company issued 2021 business update.</li>
	<li>SOS Limited (NYSE:<a class="ticker" href="/stock/SOS#NYSE">SOS</a>) dropped 10.5% to close at $5.01 as the company priced its 25 million ADS offering at $5 per ADS.</li>
	<li>Alithya Group Inc. (NASDAQ:<a class="ticker" href="/stock/ALYA#NASDAQ">ALYA</a>) fell 9.5% to close at $2.56 after climbing around 9% on Monday.</li>
	<li>Holicity Inc. (NYSE:<a class="ticker" href="/stock/HOL#NYSE">HOL</a>) shares fell 9.3% to close at $12.25.</li>
	<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="/stock/NEXT#NASDAQ">NEXT</a>) fell 8.2% to close at $2.59 after climbing 10% on Monday. NextDecade and Oxy Low Carbon Ventures recently signed a term sheet for CO2 transportation and storage in South Texas.</li>
	<li>Danimer Scientific, Inc. (NYSE:<a class="ticker" href="/stock/DNMR#NYSE">DNMR</a>) fell 7.3% to close at $34.15 after the company reported Q4 results and announced plans to invest $700 million to expand its Bainbridge manufacturing operations and add 400-jobs in Decatur County.</li>
</ul>

66 Biggest Movers From Yesterday

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 12)

<ul>
	<li>180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="/stock/ATNF#NASDAQ">ATNF</a>) (<a href="https://www.benzinga.com/news/21/04/20581755/why-ikena-oncology-evelo-biosciences-and-180-life-sciences-are-rallying-today">moved </a> on insider buying)</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="/stock/CELC#NASDAQ">CELC</a>)</li>
	<li>Fortress Biotech, Inc. (NASDAQ:<a class="ticker" href="/stock/FBIO#NASDAQ">FBIO</a>)</li>
	<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GANX#NASDAQ">GANX</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/MMSI#NASDAQ">MMSI</a>)</li>
	<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="/stock/MDXG#NASDAQ">MDXG</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 12)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>ACADIA Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/ACAD#NASDAQ">ACAD</a>)</li>
	<li>Achilles Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/ACHL#NASDAQ">ACHL</a>) (reacted to presentation at the American Association of Cancer Research annual meeting)</li>
	<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/AFIB#NASDAQ">AFIB</a>)</li>
	<li>Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="/stock/ADVM#NASDAQ">ADVM</a>)</li>
	<li>Adagene Inc. (NASDAQ:<a class="ticker" href="/stock/ADAG#NASDAQ">ADAG</a>)</li>
	<li>Aprea Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/APRE#NASDAQ">APRE</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Biophytis SA (NASDAQ:<a class="ticker" href="/stock/BPTS#NASDAQ">BPTS</a>)</li>
	<li>Bolt Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BOLT#NASDAQ">BOLT</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>) (reacted to AACR presentation)</li>
	<li>Coherus BioSciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CHRS#NASDAQ">CHRS</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>ContraFect Corporation (NASAQ: CFRX)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/FUSN#NASDAQ">FUSN</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>Immunocore Holdings plc (NASDAQ:<a class="ticker" href="/stock/IMCR#NASDAQ">IMCR</a>)</li>
	<li>IMARA Inc. (NASDAQ:<a class="ticker" href="/stock/IMRA#NASDAQ">IMRA</a>)</li>
	<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/TIL#NASDAQ">TIL</a>) (moved on AACR presentation)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>) (reacted to preclinical data presented at AACR meeting)</li>
	<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/LBPH#NASDAQ">LBPH</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/QLGN#NASDAQ">QLGN</a>) (<a href=" https://www.benzinga.com/general/biotech/21/04/20573957/why-is-qualigen-stock-trading-lower-today">withdrew </a> emergency use authorization application for COVID-19 diagnostic test)</li>
	<li>Reata Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RETA#NASDAQ">RETA</a>)</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RPHM#NASDAQ">RPHM</a>) (went public&nbsp;Friday)</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/RVPH#NASDAQ">RVPH</a>)</li>
	<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRPT#NASDAQ">SRPT</a>)</li>
	<li>Sigilon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SLNO#NASDAQ">SLNO</a>)</li>
	<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SYRS#NASDAQ">SYRS</a>)</li>
	<li>Titan Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/TTNP#NASDAQ">TTNP</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>) (went public Friday)</li>
	<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/YMAB#NASDAQ">YMAB</a>) (presented clinical data at AACR meeting)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Amarin Names Insider Karim Mikhail As CEO</h3>

Amarin Corporation plc (NASDAQ:<a class="ticker" href="/stock/AMRN#NASDAQ">AMRN</a>) announced that CEO John Thero has informed the board of directors of his plan to retire from the position of CEO&nbsp;effective Aug. 1. He will also step down from the board at that time.

The board has appointed Karim Mikhail, Amarin&#39;s senior SVP and head of commercial for Europe, to succeed Thero as the company&#39;s next president and CEO and as a board member. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021, the company said.

The stock was down 2.74% premarket at $5.68.&nbsp;

<h3>Johnson &amp; Johnson&#39;s Vaccine Use Paused By FDA</h3>

The Food and Drug Administration and the Centers for Disease Control and Prevention are <a href="https://www.benzinga.com/general/biotech/21/04/20595814/fda-recommends-pause-in-use-of-johnson-johnsons-covid-19-vaccine-on-blood-clot-concerns">recommending a pause</a> in the use of Johnson &amp; Johnson&#39;s (NYSE:<a class="ticker" href="/stock/JNJ#NYSE">JNJ</a>) COVID-19 vaccine due to reports of a rare type of blood clots.

The stock was down 2.68% at $157.30 in premarket trading Tuesday.

<h3>Roche Snags&nbsp;FDA Approval For Self-Injectable, Prefilled Syringe For Asthma Drug</h3>

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) said the U.S. Food and Drug Administration has approved its supplemental Biologics License Application for Xolair, a prefilled syringe for self-injection across all approved U.S. indications.

Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria and nasal polyps.

<h3>Immunocore Presents Positive Phase 3 Data For Eye Cancer Drug</h3>

Immunocore presented at the AACR annual meeting with&nbsp;data from a Phase 3 trial comparing tebentafusp with investigator&#39;s choice, in first-line metastatic uveal melanoma, showing tebentafusp demonstrated a statistically significant and clinically meaningful improvement in overall survival as a first-line treatment for the condition.&nbsp;Treatment-related adverse events were manageable and consistent with the proposed mechanism.

The stock rose 3.57% to $33.37 in after-hours trading.

<h3>Burning Rock Biotech&#39;s Liquid Biopsy Assay Performs Strongly In&nbsp;Midstage Study</h3>

Burning Rock Biotech Limited (NASDAQ:<a class="ticker" href="/stock/BNR#NASDAQ">BNR</a>) announced the publication in Nature Biotechnology of results from a FDA-led Sequencing Quality Control Phase 2 study.

The data shows the liquid biopsy assay has achieved strong performance. For samples at a 25ng input, Burning Rock&#39;s assay was the most accurate assay, with roughly equivalent sensitivity but superior precision compared to other assays, the company said.&nbsp;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20567086/the-week-ahead-in-biotech-april-11-17-avenue-therapeutics-fda-decision-and-conference-presentatio"> The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight </a>

<h3>Lilly-Innovent Presents Positive Late-Stage Tyvyt Data&nbsp;In Second-Line Lung Cancer Setting</h3>

Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) and Hong Kong-based partner Innovent Biologics presented at the AACR annual meeting with results of the Phase 3 ORIENT-3 study evaluating Tyvyt versus the&nbsp; chemotherapy medication docetaxel as a second-line treatment for advanced or metastatic squamous non-small cell lung cancer.

The presentation shows that Tyvyt demonstrated a statistically significant improvement in overall survival compared to docetaxel, meeting the pre-specified primary endpoint.

The median progression-free survival as assessed by investigators was 4.3&nbsp;months versus 2.79 months, and the confirmed objective response rate was 25.5% versus 2.2%, respectively. Safety was consistent with previous studies of Tyvyt and no new safety signals were identified.

<h3>Tiziana to Seek Nasdaq Listing For Former Subsidiary Accustem</h3>

Tiziana Life Sciences PLC (NASDAQ:<a class="ticker" href="/stock/TLSA#NASDAQ">TLSA</a>) announced that its former subsidiary&nbsp;Accustem Sciences Limited&nbsp;intends to file a listing application with the Nasdaq after completion of the distribution of shares in Accustem to Tiziana shareholders.

The Nasdaq listing venue is more appropriate to the nature of Accustem&#39;s business in the view of Accustem&#39;s board.&nbsp;

The stock was trading 0.69% higher at $706.80 premarket Tuesday.

<h3>Offerings</h3>

Liquidia Corporation (NASDAQ:<a class="ticker" href="/stock/LQDA#NASDAQ">LQDA</a>) said it has entered into a common stock purchase agreement with certain institutional, accredited investors for the private placement of 8.626 million shares of common stock at a purchase price of $2.52 per share. The private placement is expected to close Tuesday and yield gross proceeds of approximately $21.7 million.

<h3>On The Radar</h3>

<h3>Clinical Readouts</h3>

Affimed N.V. (NASDAQ:<a class="ticker" href="/stock/AFMD#NASDAQ">AFMD</a>) will present at the AACR annual meeting initial clinical data from an investigator-sponsored Phase 1 study evaluating cord blood-derived natural killercells pre-complexed with Affimed&#39;s innate cell engager AFM13. The company&#39;s shares reacted positively Friday&nbsp;when the company released a statement elaborating on data from the study.

Auris Medical Holding Ltd. (NASDAQ:<a class="ticker" href="/stock/EARS#NASDAQ">EARS</a>) is scheduled to provide a business update on its pre-clinical asset AM-301. AM-301 is being evaluated for protection against airborne viruses and allergens.&nbsp;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

Biotech

Health Care

Offerings

The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 13)

<ul>
	<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="/stock/TECH#NASDAQ">TECH</a>)</li>
	<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="/stock/CELC#NASDAQ">CELC</a>)</li>
	<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/MEDP#NASDAQ">MEDP</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="/stock/MDXG#NASDAQ">MDXG</a>)</li>
	<li>Natus Medical Incorporated (NASDAQ:<a class="ticker" href="/stock/NTUS#NASDAQ">NTUS</a>)</li>
	<li>NovoCure Limited (NASDAQ:<a class="ticker" href="/stock/NVCR#NASDAQ">NVCR</a>) (<a href="https://www.benzinga.com/intraday-update/21/04/20604757/12-health-care-stocks-moving-in-tuesdays-intraday-session">reacted </a> to positive independent Data Monitoring Committee review of pivotal Phase 3 study data for lung cancer treatment candidate)</li>
	<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/THTX#NASDAQ">THTX</a>)</li>
	<li>Zymeworks Inc. (NYSE:<a class="ticker" href="/stock/ZYME#NYSE">ZYME</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 13)

<ul>
	<li>Acutus Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/AFIB#NASDAQ">AFIB</a>) (announced FDA clearance for AcQCross family of universal transseptal crossing devices)</li>
	<li>Adverum Biotechnologies, Inc. (NASDAQ:<a class="ticker" href="/stock/ADVM#NASDAQ">ADVM</a>)</li>
	<li>Aprea Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/APRE#NASDAQ">APRE</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Athenex, Inc. (NASDAQ:<a class="ticker" href="/stock/ATNX#NASDAQ">ATNX</a>)</li>
	<li>Atreca, Inc. (NASDAQ:<a class="ticker" href="/stock/BCEL#NASDAQ">BCEL</a>)</li>
	<li>Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/RNA#NASDAQ">RNA</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Celyad Oncology SA (NASDAQ:<a class="ticker" href="/stock/CYAD#NASDAQ">CYAD</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>)</li>
	<li>Coherus BioSciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CHRS#NASDAQ">CHRS</a>)</li>
	<li>ContraFect Corporation (NASAQ: CFRX)</li>
	<li>Decibel Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DBTX#NASDAQ">DBTX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>)</li>
	<li>Homology Medicines, Inc. (NASDAQ:<a class="ticker" href="/stock/FIXX#NASDAQ">FIXX</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>IMARA Inc. (NASDAQ:<a class="ticker" href="/stock/IMRA#NASDAQ">IMRA</a>)</li>
	<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IONS#NASDAQ">IONS</a>)</li>
	<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="/stock/IRTC#NASDAQ">IRTC</a>) (announced revenue impact from recently published Medicare reimbursement rate by Novitas)</li>
	<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>)</li>
	<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LIXT#NASDAQ">LIXT</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>Nabriva Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/NBRV#NASDAQ">NBRV</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>Osmotica Pharmaceuticals plc (NASDAQ:<a class="ticker" href="/stock/OSMT#NASDAQ">OSMT</a>)</li>
	<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="/stock/PRFX#NASDAQ">PRFX</a>)</li>
	<li>Pulmatrix, Inc. (NASDAQ:<a class="ticker" href="/stock/PULM#NASDAQ">PULM</a>) (reacted to termination of license agreement for Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>))</li>
	<li>Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/QLGN#NASDAQ">QLGN</a>)</li>
	<li>Reata Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RETA#NASDAQ">RETA</a>)</li>
	<li>Relay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/RLAY#NASDAQ">RLAY</a>)</li>
	<li>Reneo Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RPHM#NASDAQ">RPHM</a>) (IPOed Friday)</li>
	<li>Repro Med Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/KRMD#NASDAQ">KRMD</a>)</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/RVPH#NASDAQ">RVPH</a>)</li>
	<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SRPT#NASDAQ">SRPT</a>)</li>
	<li>Syros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SYRS#NASDAQ">SYRS</a>)</li>
	<li>Titan Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/TTNP#NASDAQ">TTNP</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>) (IPOed Friday)</li>
	<li>Voyager Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/VYGR#NASDAQ">VYGR</a>)</li>
	<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/YMAB#NASDAQ">YMAB</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Novavax Announces Departure of CFO, Executive Appointments</h3>

Novavax, Inc. (NASDAQ:<a class="ticker" href="/stock/NASDAQ#NASDAQ">NASDAQ</a>) announced CFO Greg Covino will step down for personal reasons and will take on a new role as executive adviser to the company. John Trizzino, EVP, chief commercial officer and chief business officer, will assume the CFO role on an interim basis while a search is underway for a replacement.

The company also announced the promotion of Gale Smith to the role of SVP, Discovery and Pre-Clinical Research and chief scientist, and the appointment of biopharma industry veteran Troy Morgan as SVP, chief compliance officer.

The stock was down 1.37% to $192 in after-hours trading.

<h3>Flexion Expects Q1 Revenues to Be Roughly In Line With Estimates Despite COVID Impact</h3>

Flexion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FLXN#NASDAQ">FLXN</a>) announced preliminary first-quarter revenues, comprising solely Zilretta sales, of $24.6 million, roughly in line with the $25.23 million consensus estimate. Zilretta is an FDA-approved medication indicated to treat osteoarthritis of the knee. The company expects full-year revenues of $120 million to $130 million. Analysts, on average, estimate net sales of $137.42 million.

The stock rose 5.96% to $9.96 in after-hours trading.

<h3>Zai Labs Announces Cancer Collaboration Deal With Preclinical Biotech RubrYc</h3>

Zai Lab Limited (NASDAQ:<a class="ticker" href="/stock/ZLAB#NASDAQ">ZLAB</a>) announced an R&amp;D collaboration and license option agreement with preclinical biotherapeutics company RubrYc, under which both companies will collaborate to identify product candidates using RubrYc&#39;s Discovery Engine, which leverages machine learning and structural data to identify antibodies that bind to subdominant epitopes and exhibit differentiated activity for an undisclosed oncology target.

On exercising of the licensing option, Zai Lab will have exclusive global rights to develop and commercialize product(s) of the collaboration. RubrYc will receive an upfront payment and is eligible to receive future research, development and commercialization milestones on a per candidate basis, along with royalties on worldwide net sales of each product.

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

<h3>Longboard Spikes On No Major News</h3>

Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/LBPH#NASDAQ">LBPH</a>), which IPOed recently, was found rallying ahead of the closing of the offering.

The stock surged up 33.22% to $15.80 in after-hours trading.

<h3>Gilead&#39;s Antibody-drug Conjugate Approved For Urothelial Cancer</h3>

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/GILD#NASDAQ">GILD</a>) said the U.S. Food and Drug Administration has granted accelerated approval of Trodelvy, an antibody-drug conjugate, for use in adult patients with locally advanced or metastatic urothelial cancer, who have previously received a platinum-containing chemotherapy and immunotherapy. The Trodelvy U.S. prescribing Information has a boxed warning for severe or life-threatening neutropenia and severe diarrhea.

<h3>Merck, TILT to Collaborate For Phase 1 Study of Oncolytic Virus-Keytruda Combo For Ovarian Cancer</h3>

TILT Biotherapeutics, clinical-stage biotech developing cancer immunotherapeutics, announced a clinical trial collaboration agreement with Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="/stock/MRK#NYSE">MRK</a>) to evaluate TILT&#39;s adenoviral cancer immunotherapy TILT-123, a dual cytokine armed oncolytic adenovirus, in combination with Keytruda, in a Phase I dose escalation trial in platinum-resistant or refractory ovarian cancer.

<h3>J&amp;J to Delay COVID-19 Vaccine Rollout and Trials In Europe Following U.S. Regulatory Decision to Pause</h3>

In response to the <a href="https://www.benzinga.com/news/21/04/20606157/can-nio-stock-go-from-40-to-400-in-18-months">pause recommendation</a> for the use of its COVID-19 vaccine, J&amp;J said it is reviewing the cases with European health authorities in a bid to proactively delay the rollout of its vaccine in Europe and pause vaccinations in all its COVID-19 vaccine clinical trials.

&quot;We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public,&quot; the company added.

<h3>Moderna Announces Positive Preclinical Data For COVID-19 Variant-specific Vaccine Candidates</h3>

Moderna, Inc. (NASDAQ:<a class="ticker" href="/stock/MRNA#NASDAQ">MRNA</a>) announced new results from a preclinical study of the its COVID-19 variant-specific vaccine candidates showed that the variant-specific booster vaccine candidates - mRNA-1273.351 and mRNA-1273.211 - increase neutralizing titers against SARS-CoV-2 variants of concern.

The company also said it remains on track to deliver the second 100 million doses to the U.S. government by end of May 2021 followed by another 100 million additional doses by end of July 2021.

The stock was higher by 1.92% to $152.59 in the after-hours trading.

<h3>Lilly Out-licenses Rights to Parkinson&#39;s Disease Antibody Therapy In Greater China Region</h3>

SciNeuro Pharma announced an exclusive license agreement with Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) for the development and commercialization of alpha-synuclein targeted antibody therapies for the treatment of Parkinson&#39;s disease, in Greater China, which includes mainland China, Hong Kong, Macau and Taiwan.

Under the terms of the agreement, SciNeuro has obtained an exclusive license to alpha-synuclein targeted antibodies developed by Lilly, within Greater China. Lilly will receive an upfront cash payment, in addition to downstream milestones and royalties on products developed and commercialized by SciNeuro. Lilly retains all rights outside Greater China.

The stock was up 0.37% to $183.20 in premarket trading Wednesday.

<h3>Offerings</h3>

Satsuma Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/STSA#NASDAQ">STSA</a>) said selling shareholders may offer and sell up to 14.085 million shares of our common stock from time to time in one or more offerings.

The stock slid 9.85% to $4.85 in after-hours trading.

Earnings

The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 14)

<ul>
	<li>10x Genomics, Inc. (NASDAQ:<a class="ticker" href="/stock/TXG#NASDAQ">TXG</a>)</li>
	<li>Affimed N.V. (NASDAQ:<a class="ticker" href="/stock/AFMD#NASDAQ">AFMD</a>)</li>
	<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="/stock/TECH#NASDAQ">TECH</a>) - announced out-licensing of antibody treatment candidate to Xencor, Inc. (NASDAQ:<a class="ticker" href="/stock/XNCR#NASDAQ">XNCR</a>)</li>
	<li>BioNTech SE (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>) - reacted to increased EU orders for its COVID-19 vaccine in the wake of the Johnson &amp; Johnson (NYSE:<a class="ticker" href="/stock/JNJ#NYSE">JNJ</a>) <a href="https://www.benzinga.com/general/biotech/21/04/20595814/fda-recommends-pause-in-use-of-johnson-johnsons-covid-19-vaccine-on-blood-clot-concerns">setback</a>&nbsp;</li>
	<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="/stock/GMED#NYSE">GMED</a>)</li>
	<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/MEDP#NASDAQ">MEDP</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/MMSI#NASDAQ">MMSI</a>)</li>
	<li>Natus Medical Incorporated (NASDAQ:<a class="ticker" href="/stock/NTUS#NASDAQ">NTUS</a>)</li>
	<li>NuVasive, Inc. (NASDAQ:<a class="ticker" href="/stock/NUVA#NASDAQ">NUVA</a>)</li>
	<li>PLx Pharma Inc. (NASDAQ:<a class="ticker" href="/stock/PLXP#NASDAQ">PLXP</a>)</li>
	<li>PPD, Inc. (NASDAQ:<a class="ticker" href="/stock/PPD#NASDAQ">PPD</a>) - moved on rumors of a potential buyout by Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="/stock/TMO#NYSE">TMO</a>)</li>
	<li>ShockWave Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/SWAV#NASDAQ">SWAV</a>)</li>
	<li>Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SUPN#NASDAQ">SUPN</a>)</li>
	<li>Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="/stock/ZBH#NYSE">ZBH</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 14)

<ul>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Celyad Oncology SA (NASDAQ:<a class="ticker" href="/stock/CYAD#NASDAQ">CYAD</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>)</li>
	<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LIXT#NASDAQ">LIXT</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>Nabriva Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/NBRV#NASDAQ">NBRV</a>)</li>
	<li>Osmotica Pharmaceuticals plc (NASDAQ:<a class="ticker" href="/stock/OSMT#NASDAQ">OSMT</a>)</li>
	<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/RVPH#NASDAQ">RVPH</a>)</li>
	<li>Titan Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/TTNP#NASDAQ">TTNP</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Regenxbio Doses First Patient In Gene Therapy Study</h3>

REGENXBIO Inc. (NASDAQ:<a class="ticker" href="/stock/RGNX#NASDAQ">RGNX</a>) said it dosed the first patient in Cohort 3 of the ongoing Phase I/2 trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II, also known as Hunter Syndrome, in patients up to five years old.

RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase enzyme using the AAV9 vector. RGX-121 is administered directly to the central nervous system.

The stock gained 5.4% to $37.25 in after-hours trading.

<h3>Novavax Confirms Participation In Combination COVID-19 Vaccine Study In UK</h3>

Novavax, Inc. (NASDAQ:<a class="ticker" href="/stock/NVAX#NASDAQ">NVAX</a>) said it is participating in a newly expanded investigator-initiated Phase 2 clinical trial called &quot;Comparing COVID-19 Vaccine Schedule Combinations &ndash; Stage 2,&quot;&nbsp;dubbed Com-COV2, to be conducted by the University of Oxford and supported by the U.K. Vaccines Taskforce.

Novavax&#39;s recombinant protein vaccine candidate&nbsp;NVX-CoV2373&nbsp;is one of four COVID-19 vaccines that will be studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.

The stock was up 2.18% premarket to $205.72.

<h3>Pacira Initiates Legal Proceedings Against Publication</h3>

Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="/stock/PCRX#NASDAQ">PCRX</a>) said it has filed a lawsuit against the American Society of Anesthesiologists and various other defendants, seeking pecuniary damages and the retraction of three articles that it said create the false and misleading impression that its <a href="https://amp.benzinga.com/amp/content/20516643">Exparel </a> is not an effective analgesic.

The stock was down 1.35% to $68.49 in premarket trading Thursday.

<h3>Bristol-Myers Squibb Announces European Approval For Kidney Cancer Combo Treatment&nbsp;</h3>

Bristol-Myers Squibb (NYSE:<a class="ticker" href="/stock/BMY#NYSE">BMY</a>) said the European Commission has approved its Opdivo in combination with Exelixis, Inc.&#39;s (NASDAQ:<a class="ticker" href="/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma.

<h3>Merck Pulls Plug On COVID-19 Asset, Shelves Study of Another In Hospitalized COVID-19 Patients</h3>

Merck (NYSE:<a class="ticker" href="/stock/MRK#NYSE">MRK</a>) and partner Ridgeback Biotherapeutics said a decision has been made to proceed with the Phase 3 portion of MOVe-OUT in outpatients with COVID-19&nbsp;evaluating the 800 mg dose of molnupiravir twice daily.

Yet the companies have decided not to proceed with the Phase 3 study of molnupiravir in hospitalized patients, as data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate a clinical benefit in this population.

Separately, Merck announced the discontinuation of development of MK-7110 for the treatment of hospitalized patients with COVID-19. The company acquired MK-7110 in December 2020 through its acquisition of OncoImmune.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20567086/the-week-ahead-in-biotech-april-11-17-avenue-therapeutics-fda-decision-and-conference-presentatio"> The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight </a>

<h3>Roche Reports Positive Long-Term Phase 2/3 Data For Spinal Muscular Dystrophy Treatment In Infants</h3>

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) announced new two-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi in infants&nbsp;ages&nbsp;1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy.

The data shows Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support.

The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation. Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalizations compared to the natural course of Type 1 SMA. Safety for Evrysdi was consistent with its established safety profile.

<h3>Neuronetics Names Robert Cascella As Chairman</h3>

Neuronetics, Inc. (NASDAQ:<a class="ticker" href="/stock/STIM#NASDAQ">STIM</a>) announced that Brian Farley will retire from its board and his role as chairman following its annual shareholder meeting scheduled for May 27. The company named Robert Cascella, who joined the board on April 1, as chairman of its board following Farley&#39;s retirement. The board will now have seven members.

<h3>InspireMD Announces 1-For-15 Reverse Split</h3>

InspireMD, Inc. (NYSE:<a class="ticker" href="/stock/NSPR#NYSE">NSPR</a>) announced a 1-for-15 reverse split of its common stock&nbsp;effective April 26. Beginning on April 27, the stock will trade on the NYSE American on a split-adjusted basis.

The stock was down 9.15% premarket at 50 cents.&nbsp;

<h3>Compass Announces Publication Of Positive Results For&nbsp;Depression Drug</h3>

COMPASS Pathways plc (NASDAQ:<a class="ticker" href="/stock/CMPS#NASDAQ">CMPS</a>) announced publication of the results of an exploratory study in the New England Journal of Medicine&nbsp;showing signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram&nbsp;for major depressive disorder.

COMP360 is Compass&#39; proprietary formulation of synthetic psilocybin.

<h3>AbCellera Announces Collaboration Agreement For Antibody Drug Discovery</h3>

AbCellera Biologics Inc. (NASDAQ:<a class="ticker" href="/stock/ABCL#NASDAQ">ABCL</a>) and Empirico announced&nbsp; a strategic multi-target discovery collaboration.

Through each company&#39;s proprietary technologies, the multi-target collaboration leverages hyper-scale datasets, machine learning&nbsp;and advanced computation to both identify high-value, genetically validated drug targets and discover novel therapeutic antibodies, the companies said.

Under the terms of the agreement, Empirico will have the rights to develop and commercialize novel antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products from Empirico.

Abcellera shares were up 2.65% to $29 in premarket trading Thursday.

<h3>On The Radar</h3>

<h3>Clinical Readouts</h3>

Chinook Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/KDNY#NASDAQ">KDNY</a>) will present at the the International Society of Nephrology&#39;s World Congress of Nephrology with&nbsp;Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing Phase 1 study of BION-1301 in immunoglobin A nephropathy, as well as data from the Phase 1 intravenous to subcutaneous bioavailability study in healthy volunteers.

<h3>Earnings</h3>

<ul>
	<li>Affimed N.V. (NASDAQ:<a class="ticker" href="/stock/AFMD#NASDAQ">AFMD</a>) (before the market open)</li>
	<li>Centogene N.V. (NASDAQ:<a class="ticker" href="/stock/CNTG#NASDAQ">CNTG</a>) Centogene N.V. (NASDAQ:<a class="ticker" href="/stock/CNTG#NASDAQ">CNTG</a>) (before the market open)</li>
	<li>Adamis Pharmaceuticals Corporation (NASDAQ:<a class="ticker" href="/stock/ADMP#NASDAQ">ADMP</a>)</li>
</ul>

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split

Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week&#39;s news flow was fairly light. The American Association of Cancer Research&#39;s annual meeting provided a platform for oncology-focused biopharma companies to present data from their clinical programs.

A negative headline on COVID-19 vaccine, however, marred the week. The Food and Drug Administration and the Centers for Disease Control and Prevention <a href=" https://www.benzinga.com/general/biotech/21/04/20595814/fda-recommends-pause-in-use-of-johnson-johnsons-covid-19-vaccine-on-blood-clot-concerns"> announced </a> their recommendation to pause the use of Johnson &amp; Johnson&#39;s (NYSE:<a class="ticker" href="/stock/JNJ#NYSE">JNJ</a>) COVID-19 vaccine following incidences of severe clots.

J&amp;J&#39;s pain turned into&nbsp;<a href=" https://www.benzinga.com/general/biotech/21/04/20597784/why-vaccine-stocks-pfizer-biontech-moderna-and-novavax-are-higher"> gains </a> for other COVID-19 vaccine companies. Moderna, Inc. (NASDAQ:<a class="ticker" href="/stock/MRNA#NASDAQ">MRNA</a>) added about 20% during the week, with positive preclinical data on variant-specific COVID-19 vaccines and positive analyst actions adding strength to the rally.

Avenue Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="/stock/ATXI#NASDAQ">ATXI</a>) shares spiked ahead of the PDUFA date for its pain drug. With the company announcing Tuesday it has not heard yet from the FDA and the review is continuing, the shares lost about 42% for the week from Monday&#39;s intra-day high of $7.54.

Here are the key catalysts for the unfolding week:

<h3>Conferences</h3>

American Academy of Neurology, or AAN, 2021 Annual Meeting (virtual): April 17-22 
Bloom Burton &amp; Co. Healthcare Investor Conference: April 20-21

<h3>Clinical Readouts/Presentations</h3>

AAN Meeting Presentations 

Prothena Corporation plc (NASDAQ:<a class="ticker" href="/stock/PRTA#NASDAQ">PRTA</a>): results from the Phase 1 study of PRX004 in ATTR amyloidosis, a rare disorder that occurs when there is a buildup of amyloid proteins in the body (Sunday, at 3-4:30 p.m.)

Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALNY#NASDAQ">ALNY</a>): full 9-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi drug for treating polyneuropathy of hereditary ATTR amyloidosis, a genetic disorder affecting a protein called&nbsp;transthyretin, produced in the liver&nbsp;(Monday, 2 p.m.)

Standalone Releases 

Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/SNDX#NASDAQ">SNDX</a>) will host a conference call and live webcast at 8 a.m. on Tuesday to provide updated data from the Phase 1 dose escalation portion of its ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias.

Related Link: <a href=" https://www.benzinga.com/analyst-ratings/analyst-color/21/04/20601968/why-this-bristol-myers-squibb-stock-analyst-is-turning-bullish-on-the-pharma-compan"> Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company&#39;s Pipeline </a>

<h3>Earnings</h3>

Tuesday 

Johnson &amp; Johnson (before the market open) 
Abbott Laboratories (NYSE:<a class="ticker" href="/stock/ABT#NYSE">ABT</a>) (before the market open) 
Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="/stock/ISRG#NASDAQ">ISRG</a>) (after the close)

Thursday 

Biogen Inc. (NASDAQ:<a class="ticker" href="/stock/BIIB#NASDAQ">BIIB</a>) (before the market open) 
Quest Diagnostics Incorporated (NASDAQ:<a class="ticker" href="/stock/DGX#NASDAQ">DGX</a>) (before the market open)

<h3>IPOs</h3>

IPO Pricing 

Mountainview, California-based Neuropace Inc. has filed with the SEC to offer 5.313 million shares in an initial public offering, priced between $15 and $17. The commercial-stage medical device company manufactures brain-responsive neuromodulation system for epilepsy treatment. Neurospace&nbsp;expects to list its common stock on the Nasdaq under the ticker symbol NPCE.

Zymergen Inc. is&nbsp;an Emeryville, California-based company that engineers microbes to make novel biomolecules used in various products. The company&nbsp;proposes to offer 13.6 million shares at an estimated price range of $28-$31. The company has applied for listing its shares on the Nasdaq under the ticker symbol ZY.

IPO Quiet Period Expiry 

Lava Therapeutics B.V. (NASDAQ:<a class="ticker" href="/stock/LVTX#NASDAQ">LVTX</a>) 
Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) 
Edgewise Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/EWTX#NASDAQ">EWTX</a>) 
Ikena Oncology, Inc. (NASDAQ:<a class="ticker" href="/stock/IKNA#NASDAQ">IKNA</a>) 
Achilles Therapeutics plc (NASDAQ:<a class="ticker" href="/stock/ACHL#NASDAQ">ACHL</a>)

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

Photo by&nbsp;<a href="https://unsplash.com/@thoughtcatalog?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Thought Catalog</a>&nbsp;on&nbsp;<a href="https://unsplash.com/s/photos/drug?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a>

Previews

The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Design Therapeutics (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) with a Overweight rating and announces Price Target of $42.

Price Target

Initiation

Analyst Ratings

Piper Sandler Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $42

Goldman Sachs analyst Graig Suvannavejh initiates coverage on Design Therapeutics (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) with a Neutral rating and announces Price Target of $28.

Goldman Sachs Initiates Coverage On Design Therapeutics with Neutral Rating, Announces Price Target of $28

SVB Leerink analyst Joseph Schwartz initiates coverage on Design Therapeutics (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) with a Outperform rating and announces Price Target of $36.

SVB Leerink Initiates Coverage On Design Therapeutics with Outperform Rating, Announces Price Target of $36

Upgrades

Downgrades

Intraday Update

Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 20)

<ul>
	<li>Alexion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALXN#NASDAQ">ALXN</a>)</li>
	<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="/stock/ATRC#NASDAQ">ATRC</a>)</li>
	<li>BioNTech SE (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>)</li>
	<li>China Biologic Products Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/CBPO#NASDAQ">CBPO</a>) (announced completion of going private transaction)</li>
	<li>Dicerna Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/DRNA#NASDAQ">DRNA</a>)</li>
	<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="/stock/IART#NASDAQ">IART</a>)</li>
	<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="/stock/MGNX#NASDAQ">MGNX</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="/stock/UTHR#NASDAQ">UTHR</a>)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="/stock/WST#NYSE">WST</a>)</li>
	<li>Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="/stock/ZBH#NYSE">ZBH</a>) (reacted to FDA 510(k) clearance of the Rosa Partial Knee System for robotically-assisted partial knee replacement surgeries)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 20)

<ul>
	<li>4D Molecular Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/FDMT#NASDAQ">FDMT</a>)</li>
	<li>ADC Therapeutics SA (NYSE:<a class="ticker" href="/stock/ADCT#NYSE">ADCT</a>)</li>
	<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="/stock/ADMA#NASDAQ">ADMA</a>)</li>
	<li>Agile Therapeutics, Inc. (AGRX)</li>
	<li>Akoya Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/AKYA#NASDAQ">AKYA</a>) (IPOed Friday)</li>
	<li>Allena Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALNA#NASDAQ">ALNA</a>)</li>
	<li>Angion Biomedica Corp. (NASDAQ:<a class="ticker" href="/stock/ANGN#NASDAQ">ANGN</a>)</li>
	<li>Applied Genetic Technologies Corporation (NASDAQ:<a class="ticker" href="/stock/AGTC#NASDAQ">AGTC</a>)</li>
	<li>Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ASMB#NASDAQ">ASMB</a>)</li>
	<li>Aurinia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/AUPH#NASDAQ">AUPH</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>Bellerophon Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/BLPH#NASDAQ">BLPH</a>)</li>
	<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="/stock/BMEA#NASDAQ">BMEA</a>) (IPOed Friday)</li>
	<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="/stock/BMRA#NASDAQ">BMRA</a>)</li>
	<li>Brainstorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/BCLI#NASDAQ">BCLI</a>)</li>
	<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="/stock/BCTX#NASDAQ">BCTX</a>)</li>
	<li>Calithera Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/CALA#NASDAQ">CALA</a>)</li>
	<li>Celyad Oncology SA (NASDAQ:<a class="ticker" href="/stock/CYAD#NASDAQ">CYAD</a>)</li>
	<li>Checkmate Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CMPI#NASDAQ">CMPI</a>)</li>
	<li>ChemoCentryx, Inc. (NASDAQ:<a class="ticker" href="/stock/CCXI#NASDAQ">CCXI</a>)</li>
	<li>Concert Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/CNCE#NASDAQ">CNCE</a>)</li>
	<li>ContraFect Corporation (NASDAQ:<a class="ticker" href="/stock/CFRX#NASDAQ">CFRX</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) (Sell-side began initiating coverage following IPO quiet period expiry)</li>
	<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="/stock/EBS#NYSE">EBS</a>)</li>
	<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ENVB#NASDAQ">ENVB</a>)</li>
	<li>Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>)</li>
	<li>Finch Therapeutics Group, Inc. (NASDAQ:<a class="ticker" href="/stock/FNCH#NASDAQ">FNCH</a>)</li>
	<li>Foghorn Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/FHTX#NASDAQ">FHTX</a>)</li>
	<li>Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GRTX#NASDAQ">GRTX</a>)</li>
	<li>Gracell Biotechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/GRCL#NASDAQ">GRCL</a>)</li>
	<li>Fusion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/FUSN#NASDAQ">FUSN</a>)</li>
	<li>Homology Medicines, Inc. (NASDAQ:<a class="ticker" href="/stock/FIXX#NASDAQ">FIXX</a>)</li>
	<li>Idera Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/IDRA#NASDAQ">IDRA</a>)</li>
	<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/IKT#NASDAQ">IKT</a>)</li>
	<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="/stock/INM#NASDAQ">INM</a>)</li>
	<li>Karyopharm Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/KPTI#NASDAQ">KPTI</a>)</li>
	<li>Kronos Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/KRON#NASDAQ">KRON</a>)</li>
	<li>Lixte Biotechnology Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LIXT#NASDAQ">LIXT</a>)</li>
	<li>Lucira Health, Inc. (NASDAQ:<a class="ticker" href="/stock/LHDX#NASDAQ">LHDX</a>)</li>
	<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="/stock/MNOV#NASDAQ">MNOV</a>)</li>
	<li>Metacrine, Inc. (NASDAQ:<a class="ticker" href="/stock/MTCR#NASDAQ">MTCR</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>)</li>
	<li>NuCana plc (NASDAQ:<a class="ticker" href="/stock/NCNA#NASDAQ">NCNA</a>)</li>
	<li>OraSure Technologies, Inc. (NASDAQ:<a class="ticker" href="/stock/OSUR#NASDAQ">OSUR</a>)</li>
	<li>Pharvaris B.V. (NASDAQ:<a class="ticker" href="/stock/PHVS#NASDAQ">PHVS</a>)</li>
	<li>Pulmatrix, Inc. PULM)</li>
	<li>Sigilon Therapeutics, Inc (NASDAQ:<a class="ticker" href="/stock/SGTX#NASDAQ">SGTX</a>)</li>
	<li>Soleno Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/SLNO#NASDAQ">SLNO</a>)</li>
	<li>Stealth BioTherapeutics Corp (NASDAQ:<a class="ticker" href="/stock/MITO#NASDAQ">MITO</a>)</li>
	<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="/stock/UPC#NASDAQ">UPC</a>)</li>
	<li>Vaxcyte Inc (NASDAQ:<a class="ticker" href="/stock/PCVX#NASDAQ">PCVX</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>)</li>
	<li>Viveve Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/VIVE#NASDAQ">VIVE</a>)</li>
	<li>Vyne Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/VYNE#NASDAQ">VYNE</a>)</li>
	<li>Zymeworks Inc. (NYSE:<a class="ticker" href="/stock/ZYME#NYSE">ZYME</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Lilly Announces Presentation of Positive Phase 1/2 Study of Selpercatinib In RET fusion-positive Solid Tumors</h3>

Eli Lilly and Company (NYSE:<a class="ticker" href="/stock/LLY#NYSE">LLY</a>) announced that it presented at the 2021 American Association for Cancer Research Annual Meeting data from the Phase 1/2 trial showing treatment with selpercatinib demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal malignancies.

The company noted a confirmed objective response rate of 47%, with responses observed in nine unique cancer types. Median duration of response was not reached at 13 months, with 11 of 15 responses ongoing, it added. The company also said safety was consistent with the known profile of selpercatinib.

<h3>Moderna Strikes Deal to Supply Israel Variant-specific COVID Vaccine In 2022</h3>

Moderna, Inc. (NASDAQ:<a class="ticker" href="/stock/MRNA#NASDAQ">MRNA</a>) announced a new supply agreement, with Israel, under which Israel also retains an option to purchase doses of one of Moderna&#39;s variant-specific vaccine candidates in 2022, subject to regulatory approval.

This follows two earlier agreements between Israel and Moderna to supply a total of 10 million doses of the COVID-19 Vaccine. The Israeli Ministry of Health authorized COVID-19 Vaccine Moderna for use on Jan.&nbsp;4.

<h3>Lumos Announces Retirement of CFO, Names Insider to the Role</h3>

Lumos Pharma, Inc. (NASDAQ:<a class="ticker" href="/stock/LUMO#NASDAQ">LUMO</a>) said chief financial officer Carl Langren, who has been with the company for 40 years, has announced his plans to retire effective as of July 4. Langren has been serving in the current role since November&nbsp;2019.

Lori Lawley, currently SVP, Finance and Corporate Controller, will succeed Langren as CFO. The company also announced the appointment of Eddie Varnado as VP, Finance and Corporate Controller.

<h3>Evelo Presents Positive Data for Phase 1b Study of Atopic Dermatitis Drug</h3>

Evelo Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVLO#NASDAQ">EVLO</a>) presented full clinical data from the Phase 1b clinical trial cohort evaluating EDP1815 for the treatment of mild and moderate atopic dermatitis in a poster presentation at the International Society of Atopic Dermatitis. The full results reinforce the data released on January 20, demonstrating that treatment with EDP1815 resulted in clinically meaningful improvements in both patient- and physician-reported outcomes, the company said.

The stock was up 1.48% at $11 in after-hours trading.

<h3>Trevena Says Its Investigational Asset Included In Global Study For COVID-19 Treatment</h3>

Trevena, Inc. (NASDAQ:<a class="ticker" href="/stock/TRVNA#NASDAQ">TRVNA</a>) said its TRV027 has been selected for inclusion in an international, multi-site, adaptive, Phase 2-Phase 3 trial in COVID-19 patients.

The stock was up 4.71% to $1.78 in premarket trading Wednesday.

<h3>Humanigen Announces Pharma Industry Veteran Adrian Kilcoyne as Chief Medical Officer </h3>

Humanigen, Inc. (NASDAQ:<a class="ticker" href="/stock/HGEN#NASDAQ">HGEN</a>), which is evaluating its lead drug lenzilumab for cytokine storm associated with COVID-19, said it has appointed Adrian Kilcoyne to the newly-created role of chief medical officer, effective immediately, reporting to Cameron Durrant, CEO of Humanigen.

He recently served as VP of Oncology Global Medical Affairs, Head of Evidence Generation and External Alliances, at AstraZeneca plc. (NASDAQ:<a class="ticker" href="/stock/AZN#NASDAQ">AZN</a>).

In premarket trading Wednesday, <a href="https://www.benzinga.com/general/biotech/21/03/20390403/humanigen-rallies-54-a-technical-analysis"> Humanigen shares </a> gained 1.18% to $13.70.

<h3>Applied DNA Pre-announces Above-consensus Q2 Revenues </h3>

Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/APDN#NASDAQ">APDN</a>) announced preliminary estimated second-quarter revenues in the range of $2.5 million to $2.7 million, up from $1.6 million in the first quarter and $552,000 in the year-ago quarter. Analysts, on average, estimate, revenues of $2.41 million.

The company attributed the sequential growth, principally to demand for safeCircle, its pooled COVID-19 surveillance testing program, and from sales of its Linea COVID-19 Assay Kit.

The company also said it&#39;s currently debt free.

<h3>Earnings </h3>

Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="/stock/ISRG#NASDAQ">ISRG</a>) said its first-quarter revenues climbed 18% year-over-year to $1.29 billion, and the non-GAAP net income per share climbed from $2.70 to $3.52, ahead of the $2.63 per share consensus.

The stock rose 3.81% to $842.02 in after-hours trading.

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) reported group sales of 14.93 billion francs ($16.26 billion) for the first quarter, down 1% but up 3% on a constant exchange rate. Sales of its Pharmaceutical business declined in all geographies, and the weakness was offset by a 50% increase in sales of its <a href="https://www.benzinga.com/general/biotech/21/03/20160023/roche-boosts-diagnostics-portfolio-with-1-8b-bet-on-covid-19-test-manufacturer-genmark">diagnostics business. </a> The company confirmed its outlook for 2021.

Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="/stock/EW#NYSE">EW</a>) said its first-quarter sales climbed 8% to $1.2 billion and EPS came in at 54 cents, exceeding the 47-cent per-share consensus estimate. The company raised its adjusted EPS guidance for 2021.

The stock added 3.76% to $93 in after-hours trading.

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

Guidance

The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue

<h3>Gainers</h3>

<ul>
	<li>Welbilt, Inc. (NYSE:<a class="ticker" href="/stock/WBT#NYSE">WBT</a>) shares surged 44.5% to close at $22.58 on Wednesday after The Middleby Corporation announced plans to acquire the company.</li>
	<li>Skillz Inc. (NYSE:<a class="ticker" href="/stock/SKLZ#NYSE">SKLZ</a>) jumped 33.6% to settle at $16.76.</li>
	<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="/stock/TYHT#NASDAQ">TYHT</a>) gained 31.5% to close at $6.68. Shineco, on April 14, entered into stock purchase agreements with investors.</li>
	<li>GreenBox POS (NASDAQ:<a class="ticker" href="/stock/GBOX#NASDAQ">GBOX</a>) gained 27.4% to settle at $9.72. GreenBox POS recently announced the appointment of public accounting veteran Ben Chung as its new CFO and fraud and risk management veteran Bryan Rowland as Head of Risk Management.</li>
	<li>Tiptree Inc. (NASDAQ:<a class="ticker" href="/stock/TIPT#NASDAQ">TIPT</a>) rose 26.9% to close at $14.22 after climbing 12% on Tuesday.</li>
	<li>SkyWater Technology, Inc. (NASDAQ:<a class="ticker" href="/stock/SKYT#NASDAQ">SKYT</a>) gained 26.7% to settle at $17.74 after the company priced its IPO at $14 a share.</li>
	<li>PLBY Group, Inc. (NASDAQ:<a class="ticker" href="/stock/PLBY#NASDAQ">PLBY</a>) rose 26.3% to close at $45.14. JP Morgan recently disclosed a 7.9% passive stake in PLBY Group.</li>
	<li>BioVie Inc. (NASDAQ:<a class="ticker" href="/stock/BIVI#NASDAQ">BIVI</a>) gained 26.2% to settle at $13.34.</li>
	<li>UiPath Inc. (NASDAQ:<a class="ticker" href="/stock/PATH#NASDAQ">PATH</a>) surged 23.2% to close at $69.00 as the company priced its IPO at $56 per share.</li>
	<li>inTEST Corporation (NYSE:<a class="ticker" href="/stock/INTT#NYSE">INTT</a>) shares jumped 22.2% to close at $11.66.</li>
	<li>Genius Sports Limited (NASDAQ:<a class="ticker" href="/stock/GENI#NASDAQ">GENI</a>) gained 22% to close at $19.78.</li>
	<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/ONVO#NASDAQ">ONVO</a>) surged 21.2% to settle at $9.26.</li>
	<li>MicroVision, Inc. (NASDAQ:<a class="ticker" href="/stock/MVIS#NASDAQ">MVIS</a>) jumped 20.3% to settle at $12.49.</li>
	<li>Northern Genesis Acquisition Corp. (NYSE:<a class="ticker" href="/stock/NGA#NYSE">NGA</a>) gained 18.6% to close at $15.63.</li>
	<li>Williams Industrial Services Group Inc. (NYSE:<a class="ticker" href="/stock/WLMS#NYSE">WLMS</a>) gained 18.3% to settle at $4.40. The company, last month, reported Q4 results.</li>
	<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/INMB#NASDAQ">INMB</a>) gained 18.2% to close at $13.03 after B. Riley FBR initiated coverage on the stock with a Buy rating and a price target of $29 per share.</li>
	<li>Mogo Inc. (NASDAQ:<a class="ticker" href="/stock/MOGO#NASDAQ">MOGO</a>) rose 18% to settle at $8.05.</li>
	<li>Ocugen, Inc. (NASDAQ:<a class="ticker" href="/stock/OCGN#NASDAQ">OCGN</a>) gained 17.8% to close at $6.50. Ocugen said its co-development partner Bharat Biotech announced positive results from the second interim analysis of the Phase 3 study of Covaxin, a whole virion inactivated COVID-19 vaccine candidate.</li>
	<li>Fisker Inc. (NYSE:<a class="ticker" href="/stock/FSR#NYSE">FSR</a>) rose 17.2% to settle at $15.15 in sympathy with the broader market as stocks across sectors rebound following recent selloffs.</li>
	<li>GigCapital3, Inc. (NYSE:<a class="ticker" href="/stock/GIK#NYSE">GIK</a>) gained 16.8% to settle at $9.05.</li>
	<li>Avenue Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/ATXI#NASDAQ">ATXI</a>) surged 16.4% to close at $4.55. The company recently announced FDA is still reviewing its NDA resubmission for IV tramadol and has not provided a decision.</li>
	<li>Metromile, Inc. (NASDAQ:<a class="ticker" href="/stock/MILE#NASDAQ">MILE</a>) gained 15.6% to close at $8.75.</li>
	<li>Excellon Resources Inc. (NYSE:<a class="ticker" href="/stock/EXN#NYSE">EXN</a>) surged 15.6% to settle at $3.19.</li>
	<li>Alterity Therapeutics Limited (NASDAQ:<a class="ticker" href="/stock/ATHE#NASDAQ">ATHE</a>) climbed 15.2% to close at $1.44.</li>
	<li>Desktop Metal, Inc. (NYSE:<a class="ticker" href="/stock/DM#NYSE">DM</a>) gained 14.6% to settle at $12.89.</li>
	<li>Sierra Metals Inc. (NYSE:<a class="ticker" href="/stock/SMTS#NYSE">SMTS</a>) rose 14.5% to close at $3.23. The company, last week, released Q1 results.</li>
	<li>Acme United Corporation (NYSE:<a class="ticker" href="/stock/ACU#NYSE">ACU</a>) rose 13.4% to close at $43.00. Acme United recently reported better-than-expected Q1 sales.</li>
	<li>TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="/stock/TMDX#NASDAQ">TMDX</a>) gained 13.3% to settle at $28.36. The company recently announced the FDA advisory committee panel voted 12 to 5 that the benefits of the OCS Heart System outweigh the risks.</li>
	<li>Arrival (NASDAQ:<a class="ticker" href="/stock/ARVL#NASDAQ">ARVL</a>) rose 12.1% to close at $14.59 after dropping over 6% on Tuesday.</li>
	<li>Support.com, Inc. (NASDAQ:<a class="ticker" href="/stock/SPRT#NASDAQ">SPRT</a>) rose 11.2% to close at $3.59. Support.com recently announced the purchase of a Bitcoin mining company.</li>
	<li>Acorda Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/ACOR#NASDAQ">ACOR</a>) climbed 10.8% to settle at $4.60. Hearing Motley Fool named the stock a &#39;must buy.&#39;</li>
	<li>Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="/stock/ISRG#NASDAQ">ISRG</a>) shares jumped 9.9% to settle at $891.38 after the company reported better-than-expected Q1 results.</li>
	<li>Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/SAVA#NASDAQ">SAVA</a>) gained 8.5% to close at $34.87 following Q1 earnings.</li>
	<li>Aesthetic Medical International Holdings Group Limited (NASDAQ:<a class="ticker" href="/stock/AIH#NASDAQ">AIH</a>) gained 8.4% to close at $5.80. The company recently reported better-than-expected Q4 sales results.</li>
	<li>Edwards Lifesciences Corp (NYSE:<a class="ticker" href="/stock/EW#NYSE">EW</a>) rose 6.3% to close at $95.24 after the company reported better-than-expected Q1 results and issued strong guidance.</li>
</ul>

&nbsp;

<a href="https://www.benzinga.com/investing/best-penny-stocks/">Check out these big penny stock gainers and losers</a>

<h3>Losers</h3>

<ul>
	<li>Infobird Co., Ltd (NASDAQ:<a class="ticker" href="/stock/IFBD#NASDAQ">IFBD</a>) shares dipped 21.4% to close at $4.74 on Wednesday. The company&rsquo;s shares jumped over 50% on Tuesday after the company priced its IPO at $4 per share.</li>
	<li>Unique Fabricating, Inc. (NYSE:<a class="ticker" href="/stock/UFAB#NYSE">UFAB</a>) shares fell 20% to settle at $4.04 after the company swung to a loss in the fourth quarter.</li>
	<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="/stock/DGLY#NASDAQ">DGLY</a>) fell 11.9% to close at $1.71. Former Minneapolis police officer Derek Chauvin was convicted Tuesday of second-degree murder, third-degree murder and second-degree manslaughter in the death of George Floyd, an unarmed Black man whose neck Chauvin kneeled on for more than nine minutes during an arrest last May despite Floyd&rsquo;s cries of &ldquo;I can&rsquo;t breathe!&rdquo;</li>
	<li>Esports Technologies, Inc. (NASDAQ:<a class="ticker" href="/stock/EBET#NASDAQ">EBET</a>) fell 10.2% to close at $22.50. The company recently announced the launch of its consumer platform, Gogawi, in Japan.</li>
	<li>Troika Media Group, Inc. (NASDAQ:<a class="ticker" href="/stock/TRKA#NASDAQ">TRKA</a>) fell 9.9% to settle at $2.81. Troika Media shares dipped around 25% on Tuesday after the company priced its IPO at $4.15 per share.</li>
	<li>Lava Therapeutics B.V. (NASDAQ:<a class="ticker" href="/stock/LVTX#NASDAQ">LVTX</a>) dipped 9.6% to close at $12.30. Multiple firms recently initiated coverage on the stock with a bullish rating.</li>
	<li>Brooklyn ImmunoTherapeutics, Inc. (NYSE:<a class="ticker" href="/stock/BTX#NYSE">BTX</a>) fell 9.1% to settle at $8.90.</li>
	<li>Enthusiast Gaming Holdings Inc. (NASDAQ:<a class="ticker" href="/stock/EGLX#NASDAQ">EGLX</a>) dropped 8.8% to close at $7.88.</li>
	<li>J2 Global, Inc. (NASDAQ:<a class="ticker" href="/stock/JCOM#NASDAQ">JCOM</a>) fell 8.5% to close at $118.35 after Piper Sandler downgraded the stock from Overweight to Neutral.</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>) shares dropped 8.4% to settle at $19.55 on Wednesday.</li>
	<li>Planet Green Holdings Corp. (NYSE:<a class="ticker" href="/stock/PLAG#NYSE">PLAG</a>) fell 8.3% to close at $2.20.</li>
	<li>Netflix, Inc. (NASDAQ:<a class="ticker" href="/stock/NFLX#NASDAQ">NFLX</a>) dropped 7.4% to settle at $508.90. Netflix reported better-than-expected earnings and sales results for its first quarter. However, the company said it finished the quarter with 208 million paid memberships, up 14% year over year but below the company forecast of 210 million..</li>
	<li>Inotiv, Inc. (NASDAQ:<a class="ticker" href="/stock/NOTV#NASDAQ">NOTV</a>) shares fell 6.2% to close at $19.22 after the company priced its 2,647,059 share common stock offering at $17 per share.</li>
</ul>

48 Biggest Movers From Yesterday

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 21)

<ul>
	<li>Alexion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ALXN#NASDAQ">ALXN</a>)</li>
	<li>Axonics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXNX#NASDAQ">AXNX</a>)</li>
	<li>BioNTech SE (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>)</li>
	<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="/stock/TECH#NASDAQ">TECH</a>)</li>
	<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="/stock/BSX#NYSE">BSX</a>)</li>
	<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="/stock/EW#NYSE">EW</a>) (<a href="https://www.benzinga.com/general/biotech/21/04/20721929/the-daily-biotech-pulse-moderna-to-supply-variant-specific-vaccine-to-israel-roches-diagnostics-b">reacted </a> to better-than-expected quarterly results)</li>
	<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="/stock/GMED#NYSE">GMED</a>)</li>
	<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="/stock/IART#NASDAQ">IART</a>)</li>
	<li>Intuitive Surgical, Inc. (NASDAQ:<a class="ticker" href="/stock/ISRG#NASDAQ">ISRG</a>) (announced better-than-expected quarterly results)</li>
	<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="/stock/MGNX#NASDAQ">MGNX</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>) (announced Food and Drug administration approval for Flex Embolization Device with Shield Technology)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/MMSI#NASDAQ">MMSI</a>)</li>
	<li>PRA Health Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/PRAH#NASDAQ">PRAH</a>)</li>
	<li>Prometheus Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/RXDX#NASDAQ">RXDX</a>)</li>
	<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/RXRX#NASDAQ">RXRX</a>) (went public Friday)</li>
	<li>ShockWave Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/SWAV#NASDAQ">SWAV</a>)</li>
	<li>Syneos Health, Inc. (NASDAQ:<a class="ticker" href="/stock/SYNH#NASDAQ">SYNH</a>)</li>
	<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="/stock/UTHR#NASDAQ">UTHR</a>)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="/stock/WST#NYSE">WST</a>)</li>
	<li>Zimmer Biomet Holdings, Inc. (NYSE:<a class="ticker" href="/stock/ZBH#NYSE">ZBH</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 21)

<ul>
	<li>Aprea Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/APRE#NASDAQ">APRE</a>)</li>
	<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXSM#NASDAQ">AXSM</a>)</li>
	<li>ChemoCentryx, Inc. (NASDAQ:<a class="ticker" href="/stock/CCXI#NASDAQ">CCXI</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="/stock/EBS#NYSE">EBS</a>)</li>
	<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/ENVB#NASDAQ">ENVB</a>)</li>
	<li>Evofem Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/EVFM#NASDAQ">EVFM</a>)</li>
	<li>Epizyme, Inc. (NASDAQ:<a class="ticker" href="/stock/EPZM#NASDAQ">EPZM</a>)</li>
	<li>Finch Therapeutics Group, Inc. (NASDAQ:<a class="ticker" href="/stock/FNCH#NASDAQ">FNCH</a>)</li>
	<li>Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/GRTX#NASDAQ">GRTX</a>)</li>
	<li>Gracell Biotechnologies Inc. (NASDAQ:<a class="ticker" href="/stock/GRCL#NASDAQ">GRCL</a>)</li>
	<li>Haemonetics Corporation (NYSE:<a class="ticker" href="/stock/HAE#NYSE">HAE</a>)</li>
	<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/HOTH#NASDAQ">HOTH</a>)</li>
	<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/TIL#NASDAQ">TIL</a>)</li>
	<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/LBPH#NASDAQ">LBPH</a>)</li>
	<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="/stock/LGVN#NASDAQ">LGVN</a>)</li>
	<li>Millendo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/MLND#NASDAQ">MLND</a>)</li>
	<li>Moleculin Biotech, Inc. (NASDAQ:<a class="ticker" href="/stock/MBRX#NASDAQ">MBRX</a>)</li>
	<li>Vaxcyte Inc (NASDAQ:<a class="ticker" href="/stock/PCVX#NASDAQ">PCVX</a>)</li>
	<li>VectivBio Holding AG (NASDAQ:<a class="ticker" href="/stock/VECT#NASDAQ">VECT</a>)</li>
	<li>Vyne Therapeutics Inc (NASDAQ:<a class="ticker" href="/stock/VYNE#NASDAQ">VYNE</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>KemPharm Receives $10M Milestone Payment Related To FDA Approval Of ADHD Drug</h3>

KemPharm, Inc. (NASDAQ:<a class="ticker" href="/stock/KMPH#NASDAQ">KMPH</a>) announced the receipt of a regulatory milestone payment of $10 million for the <a href="https://www.benzinga.com/general/biotech/21/03/19982356/why-ovid-kempharm-sorrento-aquestive-are-rallying"> FDA approval of Azstarys&nbsp;</a>in accordance with the recently amended definitive collaboration and license agreement with Commave Therapeutics, an affiliate of Gurnet Point Capital.

Corium, Inc., a portfolio company of Gurnet Point Capital, is leading U.S. commercialization efforts for Azstarys.

Azstarys is a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older and consists of serdexmethylphenidate, KemPharm&#39;s prodrug of d-methylphenidate, co-formulated with immediate-release d-MPH.

The stock was up 1.35% premarket at $9.04.&nbsp;

PRA Health Expands Pharmacovigilance Solution To COVID-19 Vaccines, Therapies

PRA Health announced the expansion of its pharmacovigilance solution to offer full post-marketing services for authorized COVID-19 vaccines and therapeutics, including post-authorization safety studies, delivered by real world solutions.

&quot;With more than 25 years of experience executing comprehensive pharmacovigilance and patient safety services in all key therapeutic areas including infectious diseases, PRA can work closely with drug developers and manufacturers in ensuring long-term safety and efficacy of COVID-19 vaccines and treatments,&quot; the company said.

<h3>Glaukos Expands In-Licensing Agreement For Eyelid Drug Delivery Platform For Additional Indication</h3>

Glaukos Corporation (NYSE:<a class="ticker" href="/stock/GKOS#NYSE">GKOS</a>) announced that it has entered into an amended licensing agreement with Intratus&nbsp;under which Intratus has granted Glaukos a global exclusive license for its patented Eyelid Drug Delivery Platform for application in the treatment of presbyopia.

The original agreement applied to the use of the platform for the treatment of dry eye disease, glaucoma and other corneal disorders&nbsp;such as allergy, blepharitis, conjunctivitis and related conditions.

<h3>Renalytix Gets 10-Year Government Contract For Early Stage Kidney Disease Testing Services</h3>

Renalytix AI plc (NASDAQ:<a class="ticker" href="/stock/RNLX#NASDAQ">RNLX</a>) announced that the U.S. government has granted the company a 10-year Governmentwide Acquisition Contract to provide KidneyIntelX early stage kidney disease bioprognostic testing services.

The contract, offered through the General Services Administration, covers laboratory testing services that can be provided through more than 140 U.S. government departments, agencies and affiliates.

The contract is effective as of April 15 and has a five-year term with a five-year extension option. It&#39;s&nbsp;structured as an Indefinite Delivery, Indefinite Quantity contract providing for an unlimited quantity of services over the contract term.

Under the contract, KidneyIntelX pricing is set at $950 per reportable result.

The shares were jumping 20.86% to $40.38 in premarket trading Thursday.

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20665598/the-week-ahead-in-biotech-johnson-johnson-biogen-earnings-neurology-conference-and-ipos"> The Week Ahead In Biotech: Johnson &amp; Johnson, Biogen Earnings, Neurology Conference And IPOs </a>

<h3>Yumanity Says Lead Drug Produced Target Engagement In Phase 1a Study</h3>

Yumanity Therapeutics (NASDAQ:<a class="ticker" href="/stock/YMTX#NASDAQ">YMTX</a>) reported that its lead product candidate, YTX-7739, which is in development for the treatment of Parkinson&#39;s disease, demonstrated dose-dependent decreases in target fatty acids.

This can be interpreted as evidence of in vivo target engagement&nbsp;in a Phase 1a multiple ascending dose clinical trial in healthy volunteers.

Inhibition of stearoyl-CoA desaturase has been shown to improve motor function and other disease markers in transgenic mouse models of Parkinson&#39;s disease. YTX-7739 was also observed to be generally well tolerated in the Phase 1a study, the company said.

<h3>Lexaria Commences Human Study Of Cannabidiol Formulation In Hypertension</h3>

Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="/stock/LEXX#NASDAQ">LEXX</a>) announced that its human clinical hypertension study HYPER-H21-1 is&nbsp;underway. The study will assess its patented DehydraTECH CBD formulation for its ability to control blood pressure and its impact on inflammation.

<h3>Orthofix Announces FDA Clearance For 3D-Printed Interbody Implant</h3>

Orthofix Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/OFIX#NASDAQ">OFIX</a>) announced FDA 510(k) clearance and the first patient implant of the Forza Ti TLIF Spacer System to help optimize Transforaminal Lumbar Interbody Fusion procedures.

The spacer, with Nanovate Technology, is a titanium 3D-printed interbody featuring an optimized design, porosity and surface that allows bone to grow into and through the spacer.

Interbody implants are spacers that surgeons insert between the vertebrae during spinal fusion surgery to help relieve pressure on nerves and hold the vertebrae in place while fusion occurs.

<h3>Offerings</h3>

Evolus, Inc. (NASDAQ:<a class="ticker" href="/stock/EOLS#NASDAQ">EOLS</a>) priced its public offering of 9 million shares of its common stock at a price of $9.50 per share for raising gross proceeds of about $85.5 million.

The stock was down 16.81% premarket at $9.75.&nbsp;

NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>) said it has commenced an underwritten public offering of shares of common stock. All of the shares of common stock in the offering will be sold by NeuBase.

The stock was down 14.5% premarket at $5.13.

<h3>On The Radar</h3>

<h3>Earnings</h3>

<ul>
	<li>Biogen Inc. (NASDAQ:<a class="ticker" href="/stock/BIIB#NASDAQ">BIIB</a>) (before the market open)</li>
	<li>Quest Diagnostics Incorporated (NASDAQ:<a class="ticker" href="/stock/DGX#NASDAQ">DGX</a>) (before the market open)</li>
	<li>NeuroMetrix, Inc. (NASDAQ:<a class="ticker" href="/stock/NURO#NASDAQ">NURO</a>) (before the market open)</li>
	<li>Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/PSTV#NASDAQ">PSTV</a>) (after the close)</li>
</ul>

<h3>IPOs</h3>

Mountainview, California-based Neuropace Inc. priced its upsized initial public offering of 6 million shares at $17, the upper end of the estimated price range of $15-$17. Gross proceeds from the offering are expected at $102 million.

The commercial-stage medical device company, which&nbsp;manufactures a brain-responsive neuromodulation system for epilepsy treatment, said its shares will begin trading on the Nasdaq under the ticker symbol &quot;NPCE.&quot;

Zymergen Inc, an Emeryville, California-based biofacturing company that engineers microbes to make novel biomolecules used in different products, priced its upsized IPO of 16.13 million shares at $31 versus&nbsp;the estimated price range of $28-$31. The company&#39;s shares will begin on the Nasdaq under the ticker symbol &quot;ZY.&quot;

Related Link: <a href="https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates </a>

Contracts

The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

<h3>Scaling The Peaks</h3>

(Biotech Stocks Hitting 52-week Highs April 22)

<ul>
	<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="/stock/ATRC#NASDAQ">ATRC</a>)</li>
	<li>Axonics, Inc. (NASDAQ:<a class="ticker" href="/stock/AXNX#NASDAQ">AXNX</a>)</li>
	<li>BioNTech SE (NASDAQ:<a class="ticker" href="/stock/BNTX#NASDAQ">BNTX</a>)</li>
	<li>Bio-Techne Corporation (NASDAQ:<a class="ticker" href="/stock/TECH#NASDAQ">TECH</a>)</li>
	<li>Boston Scientific Corporation (NYSE:<a class="ticker" href="/stock/BSX#NYSE">BSX</a>)</li>
	<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="/stock/EW#NYSE">EW</a>)</li>
	<li>Galectin Therapeutics Inc. (NASDAQ:<a class="ticker" href="/stock/GALT#NASDAQ">GALT</a>)</li>
	<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="/stock/GMED#NYSE">GMED</a>)</li>
	<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="/stock/IART#NASDAQ">IART</a>)</li>
	<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/LNTH#NASDAQ">LNTH</a>)</li>
	<li>IRadimed Corporation (NASDAQ:<a class="ticker" href="/stock/IRMD#NASDAQ">IRMD</a>)</li>
	<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="/stock/MGNX#NASDAQ">MGNX</a>)</li>
	<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="/stock/MEDP#NASDAQ">MEDP</a>)</li>
	<li>Medtronic plc (NYSE:<a class="ticker" href="/stock/MDT#NYSE">MDT</a>)</li>
	<li>Merit Medical Systems, Inc. (NASDAQ:<a class="ticker" href="/stock/MMSI#NASDAQ">MMSI</a>)</li>
	<li>Ortho Clinical Diagnostics Holdings plc (NASDAQ:<a class="ticker" href="/stock/OCDX#NASDAQ">OCDX</a>)</li>
	<li>PLx Pharma Inc. (NASDAQ:<a class="ticker" href="/stock/PLXP#NASDAQ">PLXP</a>)</li>
	<li>PRA Health Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/PRAH#NASDAQ">PRAH</a>) (announced expansion of its pharmacosvigilance solutions to COVID-19 vaccines and treatments)</li>
	<li>Prometheus Biosciences, Inc. (NASDAQ:<a class="ticker" href="/stock/RXDX#NASDAQ">RXDX</a>)</li>
	<li>ShockWave Medical, Inc. (NASDAQ:<a class="ticker" href="/stock/SWAV#NASDAQ">SWAV</a>) (reacted to insider selling)</li>
	<li>SI-BONE, Inc. (NASDAQ:<a class="ticker" href="/stock/SIBN#NASDAQ">SIBN</a>)</li>
	<li>Syneos Health, Inc. (NASDAQ:<a class="ticker" href="/stock/SYNH#NASDAQ">SYNH</a>)</li>
	<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="/stock/UTHR#NASDAQ">UTHR</a>)</li>
	<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="/stock/WST#NYSE">WST</a>)</li>
</ul>

<h3>Down In The Dumps</h3>

(Biotech Stocks Hitting 52-week Lows April 22)

<ul>
	<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="/stock/BMRA#NASDAQ">BMRA</a>)</li>
	<li>Design Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/DSGN#NASDAQ">DSGN</a>)</li>
	<li>Instil Bio, Inc. (NASDAQ:<a class="ticker" href="/stock/TIL#NASDAQ">TIL</a>)</li>
	<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/LBPH#NASDAQ">LBPH</a>)</li>
	<li>NeuBase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="/stock/NBSE#NASDAQ">NBSE</a>) (priced its $40 million common stock offering at a discount)</li>
	<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="/stock/SNGX#NASDAQ">SNGX</a>)</li>
</ul>

<h3>Stocks In Focus</h3>

<h3>Quidel Pre-announces Below-consensus Q1 Revenues Due to Lower Flu and Respiratory Product Revenues</h3>

Quidel Corporation (NASDAQ:<a class="ticker" href="/stock/QDEL#NASDAQ">QDEL</a>) announced preliminary first-quarter revenues of $374 million to $376 million, up an estimated 114% from the year-ago period. The guidance, however, trailed the $465.7 million consensus estimate.

The softness, according to the company, stemmed from lower sales of influenza and other respiratory disease products due to a lack of a respiratory season.

Separately, Quidel said it has completed a distribution and fulfillment agreement McKesson Corporation (NYSE:<a class="ticker" href="/stock/MCK#NYSE">MCK</a>) expedites consumer access to its non-prescription QuickVue At-Home OTC COVID-19 Test.

In after-market trading, the stock slipped 15.03% to $103.85.

<h3>Roche Announces FDA Approval For Companion Diagnostic Test For Endometrial Cancer</h3>

Roche Holding AG (OTC:<a class="ticker" href="/stock/RHHBY#OTC">RHHBY</a>) announced the U.S. Food and Drug Administration approved its VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients.

Testing can identify patients eligible for treatment with Jemperli, an anti-PD1 immunotherapy from GlaxoSmithKline plc (NYSE:<a class="ticker" href="/stock/GSK#NYSE">GSK</a>) that was approved by the FDA on 22 April 2021, the&nbsp;<a href="https://www.benzinga.com/general/biotech/21/04/20721929/the-daily-biotech-pulse-moderna-to-supply-variant-specific-vaccine-to-israel-roches-diagnostics-b">company said.</a>

Separately, Roche said the European Medicines Agency&#39;s, or EMA, Committee for Medicinal Products for Human Use, CHMP, has recommended the approval of Enspryng as the first subcutaneous treatment option for adults and adolescents from 12 years of age living with anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder, as a monotherapy or in combination with immunosuppressive therapy.

<h3>Illumina, Krators to Co-develop Companion Diagnostic For Hematologic Indications</h3>

Illumina, Inc. (NASDAQ:<a class="ticker" href="/stock/ILMN#NASDAQ">ILMN</a>) and Kartos Therapeutics, Inc. announced a new partnership to co-develop a TP53 companion diagnostic based on the content of Illumina&#39;s comprehensive genomic profiling assay, TruSight Oncology 500. This companion diagnostic for multiple hematologic indications will be the first to use TSO 500 with peripheral whole blood as a diagnostic sample type.

The initial focus of the collaboration, according to the company, will be the co-development of multiple CDx claims in blood cancers for Kartos&#39; KRT-232, a potent and selective oral MDM2 inhibitor that activates p53 to drive tumor cell death in TP53 wild-type cancers.

<h3>Verona Announces Safety Data From Pilot Study of COVID-19 Treatment</h3>

Verona Pharma plc (NASDAQ:<a class="ticker" href="/stock/VRNA#NASDAQ">VRNA</a>) announced data from a pilot study of a pressurized metered-dose inhaler formulation of ensifentrine, showing ensifentrine was safe and well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19.

The trial was not designed or sized to demonstrate clinical efficacy and no clinical efficacy benefit with ensifentrine treatment added on to standard of care was observed in the trial. One patient death was reported in the ensifentrine treatment group.

&quot;Overall, the patients in this study recovered exceptionally well, as the mortality rate in the study was much lower than aggregate data from the hospital would have suggested over the same time period,&quot; said Mike Wells, principal investigator of the study.

<h3>Gilead Files For Japanese Regulatory Approval of Filgotinib For The Additional Indication of Ulcerative Colitis</h3>

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="/stock/GILD#NASDAQ">GILD</a>) and Eisai Co., Ltd. (OTC:<a class="ticker" href="/stock/ESALY#OTC">ESALY</a>) announced that Gilead submitted an application to Japan&#39;s Pharmaceuticals and Medical Devices Agency for the approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis.

Filgotinib was approved in Japan in September&nbsp;2020 for the treatment of rheumatoid arthritis.

<h3>Eisai, Merck Submit File For Label Expansion For Combo Cancer Therapy In Uterine Body Cancer In Japan</h3>

Eisai and Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="/stock/MRK#NYSE">MRK</a>) announced the submission of an application in Japan for the additional indication of Eisai&#39;s Lenvima, in combination with Merck&#39;s <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/08/16897778/goldman-sachs-upgrades-merck-on-cancer-hiv-covid-19-pipeline">Keytruda </a> as a treatment for patients with advanced uterine body cancer.

<h3>Calliditas&#39; Lead Drug Gets Accelerated Assessment Procedure By EMA Committee In Kidney Inflammation Disease</h3>

Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="/stock/CALT#NASDAQ">CALT</a>) said its lead product candidate Nefecon, an oral formulation targeting down regulation of IgA1 for the treatment of primary IgA Nephropathy, has been granted accelerated assessment procedure by the EMA&#39;s CHMP.

If approved, Nefecon could be available to patients in Europe in H1 2022 and would become the first therapy specifically designed and approved for the treatment of IgAN, and which has the potential to be disease modifying.

<h3>Progenity Shares Higher On Momentum</h3>

Progenity, Inc. (NASDAQ:<a class="ticker" href="/stock/PROG#NASDAQ">PROG</a>) shares are surging in premarket trading Friday. The spike comes despite a lack of any company-specific announcement. Recently, there has been a series of insider buying of the company&#39;s stock.

The stock was jumping 63.25% to $4.93 in premarket trading Friday.

<h3>Genfit Names Thomas Baetz as CFO</h3>

Genfit SA (NASDAQ:<a class="ticker" href="/stock/GNFT#NASDAQ">GNFT</a>) anounced that Thomas Baetz has been appointed as chief financial officer. Baetz joins the Executive Committee, along with Stefanie Magner, chief compliance officer.

<h3>Offerings</h3>

EDAP TMS S.A. (NASDAQ:<a class="ticker" href="/stock/EDAP#NASDAQ">EDAP</a>) said it has priced its 4.15 million ADS offering at $6.75 per ADS, for raising $28 million. The closing of the offering is expected to occur on April 27, subject to customary closing conditions.

The stock slipped 12.31% to $7.41 in after-hours trading.

<h3>On The Radar</h3>

<h3>Clinical Readouts</h3>

Arena Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="/stock/ARNA#NASDAQ">ARNA</a>) announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod in participants with moderate-to-severe atopic dermatitis will be presented during a late-breaking session at the American Academy of Dermatology Virtual Meeting Experience.

The presentation will be released online at 10 am, Friday, with a live Q&amp;A session with presenter to be held Saturday.

Related Link: <a href=" https://www.benzinga.com/general/biotech/21/04/20405937/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates"> Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates</a>

<h3>IPOs</h3>

Treace Medical Concepts, Inc., a commercial-stage orthopaedic medical device company that focuses on the surgical treatment of Hallux Valgus, priced its upsized initial public offering of an aggregate of 11.25 million shares of its common stock at $17 per share.

Of the total shares offered, 6.25 million shares are being sold by Treace and 5 million by certain selling stockholders. The gross proceeds from the offering to Treace are expected to be approximately $106.3 million. Treace clarified that it will not receive any proceeds from the sale of shares by the selling stockholders

The shares are expected to begin trading on the Nasdaq under the ticker symbol TMCI.

Impel NeuroPharma, Inc., a late-stage pharma focused on therapies for patients suffering from diseases with high unmet medical needs, priced its IPO of 5.333 million shares at $15 per share, for raising gross proceeds of $80 million. All of the shares are being offered by Impel. The shares are expected to begin trading on the Nasdaq under the symbol IMPL.

Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, priced its IPO of 7.353 million shares of common stock at $17 per share. The gross proceeds to Rain from the offering, are expected to be approximately $125 million. All of the shares are being offered by Rain. The shares are expected to begin trading on the Nasdaq under the ticker symbol RAIN.

The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs

Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) reported quarterly losses of $(0.31) per share. This is a 675 percent decrease over losses of $(0.04) per share from the same period last year.

Q2 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2021-07-29
REV		(EXPECTED)2021-07-29

Q1 2021		Est.		Actual		Surprise
EPS		-0.080		-0.310		-0.2300
REV				0

Recent Quotes

Earnings

Analyst Ratings

Related Companies

Design Therapeutics Frequently Asked Questions

How do I buy Design Therapeutics (DSGN) stock?

Who are Design Therapeutics's (DSGN) competitors?

What is the target price for Design Therapeutics (DSGN) stock?

Current Stock Price for Design Therapeutics (DSGN)?

Does Design Therapeutics (DSGN) pay a dividend?

When is Design Therapeutics (NASDAQ:DSGN) reporting earnings?

Is Design Therapeutics (DSGN) going to split?

What sector and industry does Design Therapeutics (DSGN) operate in?